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THAI-ING UP THE TRIPS AGREEMENT:
ARE COMPULSORY LICENSES THE
ANSWER TO THAILAND'S
AIDS EPIDEMIC?
Stephanie Skees*
"The patent system added the fuel of interest to the fire of ge-
nius." - Abraham Lincoln
I. INTRODUCTION
In November 2006, Thailand met with international praise
after announcing its intention to issue compulsory licenses for
the HIV/AIDS 1 drug efavirenz (Stocrin).2 A compulsory license
* J.D. Candidate, California Western School of Law, Spring 2008. B.A., Uni-
versity of California, Santa Barbara. The author would like to thank all of her
friends and family for their patience and support and expresses many thanks to
Professor Gloria Sandrino for her generous guidance.
1 See Department for Health and Human Services, Centers for Disease Con-
trol and Prevention, Basic Information, http://www.cdc.gov/hiv/topics/basicindex.
htm#hiv (last visited Apr. 21, 2008). Human immunodeficiency virus (HIV) is the
retrovirus that causes AIDS. Id. Unlike most viruses, HIV attacks the immune
system, specifically white blood cells called T cells or CD4 cells. Id. Acquired im-
mune deficiency syndrome (AIDS), is the final stage of HIV infection. Id. Even
without treatment, it can take years for a person infected with HIV to reach this
final stage. Id. Having AIDS means that the virus has weakened the immune
system to the point at which the body has a difficult time fighting infections. Id. A
person is diagnosed with AIDS when that person has one or more of these opportu-
nistic infections and a low number of T cells. Id. There is presently no cure for
HIV/AIDS. Id.
2 Letter from the Department of Disease Control to Merck Sharp and Dohme
(Nov. 29, 2006), in MINISTRY OF PUB. HEALTH & NAT'L HEALTH SEC. OFFICE THAIL.,
FACTS AND EVIDENCE ON THE 10 BURNING ISSUES RELATED TO GOVERNMENT USE OF
PATENTS ON THREE PATENTED ESSENTIAL DRUGS IN THAILAND 47-48 (Vichai
Chokevivat ed., 2007), http://www.moph.go.th/hot/White%20Paper%20CL-EN.pdf
[hereinafter 10 BURNING ISSUES]. Thailand has received little opposition for issu-
ing three compulsory licenses. U.S. Senators Joseph Lieberman, Thomas Carper,
Robert Menendez, Dianne Feinstein, and Frank Lautenberg wrote a letter to Su-
san Schwab of the Office of the United States Trade Representative (USTR) to
"express concern" over the Thai government's program of compulsory licensing.
Letter from Senator Joseph Lieberman and Four U.S. Senators to Ambassador Su-
san F. Schwab (March 20, 2007), available at http://www.keionline.org/misc-docs/
liebermanplus4.pdf [hereinafter Letter from Senator Lieberman]. Additionally,
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forces the patent holder to license its patent to the issuing gov-
ernment, allowing the government to produce or import ge-
neric3 copies of the drug while paying little compensation to the
patent holder.4 In December, more than 140 organizations and
individuals sent letters to Secretary of State Condoleezza Rice
and to Susan Schwab of the Office of the United States Trade
Representative (USTR) asking the US to refrain from interfer-
Thailand was elevated from the "Watch List" to the "Priority Watch List" on the
USTR's 2007 "Special 301" Report due to "a concern that the past year has been
characterized by overall deterioration in the protection and enforcement of intel-
lectual property rights (IPR) in Thailand." Office of the United States Trade Rep-
resentative, USTR 2007 Special 301 Report, available at http://www.ustr.gov/
DocumentLibrary/Reports_ Publications/2007/2007_Special_301Review/Section
Index.html?ht., at 27. Pursuant to Section 182 of the Trade Act of 1974, as
amended by the Omnibus Trade and Competitiveness Act of 1998 and the Uru-
guay Round Agreements Act, under Special 301 provisions, the "USTR must iden-
tify those countries that deny adequate and effective protection for IPR or deny fair
and equitable market access for persons that rely on intellectual property protec-
tion." Id. at 17. The "Special 301" report is issued annually by the USTR and
carefully reviews the adequacy and effectiveness of IPR protection in 87 countries.
Id. at 2. Countries that have "the most egregious acts, policies, or practices and
whose acts, policies, or practices have the greatest adverse impact (actual or poten-
tial) on the relevant U.S. products are designated as Priority Foreign Countries."
Countries on the "Priority Watch List do not provide an adequate level of IPR pro-
tection or enforcement." Id. Countries on the "Watch List merit bilateral atten-
tion to address underlying IPR problems." Id. In reaction to Thailand's elevated
placement in the "Special 301" report, thirty five members of Congress sent a letter
to the USTR demanding that Thailand be removed from the Priority Watch List.
Letter to Ambassador Susan F. Schwab from Representative Henry Waxman and
34 Members of Congress (June 20, 2007), available at http://www.house.gov/wax-
man/pdfs/thailand%201etter%20to%20ustr%2006-20-07.pdf (arguing that Thai-
land's elevation to the Priority Watch List was in retaliation to their recent
issuance of compulsory licenses). Ambassador Schwab responded that although
the compulsory licenses for medications were considered, Thailand was placed on
the Priority Watch List for a broad range of long term IPR concerns related to
copyrights, trademarks, and patents. Letter to Representative Henry Waxman
and 34 Members of Congress from Ambassador Susan F. Schwab (July 9, 2007) (on
file with author).
3 See U.S. Food and Drug Administration, Office of Generic Drugs, http:l!
www.fda. gov/cder/consumerinfo/generic-info/generics-questionbrochure.htm
(last visited Apr. 27, 2008). After a drug patent has expired, other companies may
sell a drug under its generic name or another brand name. Id. A generic version of
a drug is required to be biologically equivalent to the previously approved drug.
Id. A biologically equivalent drug has the same rate and extent of absorption and
produces the same blood concentration levels when the two drugs are given in the
same dose and the same dosage form. Id.
4 See Grace K. Avedissian, Global Implications of a Potential U.S. Policy
Shift Toward Compulsory Licensing of Medical Inventions in a New Era of "Super-
Terrorism," 18 Am. U. INT'L L. REV. 237, 243-44 (2002).
2http://digitalcommons.pace.edu/pilr/vol19/iss2/5
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ing with Thailand's actions. 5 After receiving such a positive re-
sponse, Thailand issued two more compulsory licenses, one in
January for the AIDS drug Kaletra®6 and one in February for
the heart disease drug clopidogrel bisulfate (Plavix).7 Since
then, Thailand has announced that it is considering breaking
the patents of eleven other drugs and intends to issue at least
two more compulsory licenses by the end of 2007.8
There is no doubt that Thailand as well as many other de-
veloping countries 9 have a serious need for affordable prescrip-
tion drugs. However, pharmaceutical companies o are not non-
5 Tove Iren S. Gerhardsen, Thailand Compulsory License On AIDS Drug
Prompts Policy Debate, INTELLECTUAL PROPERTY WATCH, Dec. 22, 2006, http:ll
www.ip-watch.org/weblog/index.php?p=499&print=l&res=1280&print=l.
6 Letter from Department of Disease Control to Abbott Laboratories Ltd.
(Jan. 26, 2007), 10 BURNING ISSUES, supra note 2, at 49-50.
7 Letter from the Permanent Secretary Office to Sanofi-Synthe'labo (Thai-
land) Ltd. (Feb. 12, 2007), 10 BURNING ISSUES, supra note 2, at 51-52.
8 James Hookway & Nicholas Zamiska, Thai Showdown Spotlights Threat to
Drug Patents, WALL ST. J., Apr. 24, 2007, at Al; Thai Government to Issue Compul-
sory Licenses for Two More Drugs, KAISER DAILY HIV/AIDS REPORT, May 30, 2007,
http://www.kaisernetwork.org/daily-reports/rep-index.cfm?hint=l&DRID=
45220.
9 There are no UN or WTO definitions for "developed" or "developing" coun-
tries. World Trade Organization, Who are the Developing Countries in the WTO?,
http://www.wto.org/english/tratop-e/devel-e/dlwho-e.htm (last visited Apr. 27,
2008). Members decide for themselves whether they are "developed" or "develop-
ing." Id. In regards to its WTO membership, Thailand has declared itself a devel-
oping country. According to the UN:
[A] country is classified as a [Least Developed Country] LDC if it meets
three criteria based on: 1. low income (three year average GNI per capita
of less than U.S. $750, which must exceed $900 to leave the list, 2. human
resource weakness (based on indicators of nutrition, health, education,
and adult literacy), and 3. economic vulnerability (based on instability of
agricultural production, exports of goods and services, economic impor-
tance of non-traditional activities, merchandise export concentration, and
handicap of economic smallness). To qualify as an LDC, a country must
meet all three criteria.
United Nations, The Criteria for the Identification of the LDCs, http://www.un.org/
special-rep/ohrlls/ldc/ldc%20criteria.htm (last visited Apr. 27, 2008).
10 In this article, "pharmaceutical companies" refers to the research based
pharmaceutical companies that are members of the Pharmaceutical Research and
Manufacturers of America (PhRMA) trade association. Pharmaceutical companies
have traditionally been categorized as either research companies (e.g. Pfizer,
Merck) or generic companies without significant research programs (e.g. Mylan
Labs, Cipla Ltd.). See Pharmaceutical Research and Manufacturers of America,
http://www.phrma.org (last visited Apr. 27, 2008). The international trade associa-
tion of pharmaceutical research companies is the International Federation of
Pharmaceutical Manufacturers Association (IFPMA). See International Federa-
3
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profit organizations. They make products that save millions of
lives and that improve the quality of life for millions more, but
pharmaceutical companies are not charities. Drug manufactur-
ers, like every other company, are in business to make money.
Additionally, the products made by these companies incur huge
research and development (R&D) costs.11 The United States is
a capitalist country and corporate social responsibility is not
mandated by American laws. 12 Moreover, there are many other
factors affecting the affordability of and access to drugs in de-
veloping countries other than the price set by pharmaceutical
companies. Poor health care infrastructures and a lack of ade-
quately trained doctors and nurses contribute significantly to
the inadequate accessibility of drugs in developing countries. 13
Additionally, hidden costs in the procurement of essential
tion of Pharmaceutical Manufacturers Association, http://www.ifpma.org (last vis-
ited Apr. 27, 2008). Generic drug companies have their own trade associations,
such as Generic Pharmaceutial Association (GPhA). See Generic Pharmaceutical
Association (GPhA), http://www.gphaonline.com (last visited Apr. 27, 2008). Bio-
technology companies differ from pharmaceutical companies in that rather than
mixing chemicals to generate conventional drugs, biotech companies create far
more complex substances that mimic those produced by the human body. These
substances are made by growing live cells, extracting and then purifying their ex-
cretions. See generally What is Biotechnology?, http://www.bionewsonline.com/9/
what is biotechnology.htm (last visited September 11, 2008). Most American bi-
otech companies belong to the trade association Biotechnology Industry Organiza-
tion (Bio). See Biotechnology Industry Organization (Bio), http://www.bio.org (last
visited Apr. 27, 2008).
11 On average, it costs $800 million to develop a single new drug. PHARMACEU-
TICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA), WHAT GOES INTO THE
COST OF PRESCRIPTION DRUGS? AND OTHER QUESTIONS ABOUT YOUR MEDICINES
(2005), http://www.phrma.org/files/Cost-of Prescription-Drugs.pdf [hereinafter
Cost of Prescription Drugs].
12 See generally Cynthia A. Williams, Corporate Social Responsibility in an
Era of Economic Globalization, 35 U.C. DAVIS L. REV. 705 (2002) (discussing the
predominant academic and legal view in the U.S. on corporate social
responsibility).
13 "Limited basic infrastructure, especially in rural areas, limited health care
infrastructure and equipment, limited human resources, limited training, poor
food security and poor access to clean water, psychological and social issues, treat-
ment and monitoring costs, compliance with therapy, and logistical challenges of
supply chain management" are some of the biggest challenges to drug access. Dr.
Harvey Bale, Director General, IFPMA, Presentation at the G8 Summit: Improv-
ing Health Care in Africa 12 (May 31, 2007), http://www.ifpma.orglEvents/content/
PastEvents/pdfs/HB%20Improving%2OHealth%2OCare%2OAfrica%2031May07.
pdf [hereinafter G8 Summit].
4http://digitalcommons.pace.edu/pilr/vol19/iss2/5
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medicines 14 can more than double the price of medicines be-
tween manufacturer and patient. 15 If countries continue to ig-
nore these underlying problems and abuse compulsory licenses,
not only will developing countries suffer in the long run, but it
is the U.S. consumer that will pay the price. 16
This article will discuss how current international patent
law affects developing countries' access to medications and
whether compulsory licensing is the solution to the AIDS
epidemics in Thailand and other developing countries. It will
specifically focus on Thailand's issuance of compulsory licenses
and the ultimately harmful ramifications it will have, not only
on Thailand and other developing countries, but also on the
U.S. consumers that will be forced to unfairly bear the burden
of pharmaceutical and biotechnology R&D costs. Part II will
discuss Thailand's recent actions with regard to intellectual
14 Essential medicines are those that satisfy the priority health care needs of
the population. See World Health Organization, Essential Medicines, http://www.
who.int/topics/essential medicines/en (last visited April 27, 2008). They are se-
lected based on efficacy, safety, and comparative cost-effectiveness. Id. They are
intended to be available within health care systems at all times in adequate sup-
ply, with assured quality, and at a price the individual and the community can
afford. Id. The drugs are classified by their name and their therapeutic group.
See id. The WHO list of essential medicines has been updated every two years
since 1977. The current list is the fifteenth version dated March 2007. See World
Health Organization, WHO Model List of Essential Medicines, http://www.who.intl
medicines/publications/EssMedListl5.pdf (last visited Apr. 27, 2008).
15 The price a patient pays for medicines includes the base price (i.e. the man-
ufacturers' price) as well as additional costs for transportation, storage, import tar-
iffs and taxes, wholesale and retail markups, staff salaries, stock losses, and
procurement practices. Libby Levinson & Richard Laing, The Hidden Costs of Es-
sential Medicines, 33 WHO ESSENTIAL DRUGS MONITOR 20 (2003), http://mednet2.
who.int/edmonitor/33/edm33_en.pdf. These additional costs are due to govern-
ment health and taxation policies and health systems with outdated and ineffi-
cient procurement practices. Libby Levinson, Policy and Programming Options for
Reducing the Procurement Costs of Essential Medicines in Developing Countries
(2003) (unpublished Concentration Paper, on file with author and Boston Univer-
sity School of Public Health). Thailand is among the 20% highest countries for
customs duties on retail medicaments (15%) and for EU pharmaceutical imports
(10%). Developing Countries' Duties and Taxes on Essential Medicines Used in the
Treatment of the Major Communicable Disease (European Commission, Dir. Gen.
for Trade, Working Document, 2003), http://trade.ec.europa.eu/doclib/docs/2003/
june/tradoc 113184.pdf.
16 See Letter from Senator Lieberman, supra note 2; see also Press Release,
PhRMA, PhRMA Meets with Thai Health Minister; Highlights Consequences of
Compulsory Licenses (May 22, 2007), http://www.phrma.org/news-room/press_
release/phrma meets with thaihealth minister/ [hereinafter PhRMA Meets with
Thai Health Minister].
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property rights and the reactions and concerns those actions
raised. It will also address other options Thailand has in fight-
ing HIV/AIDS. Additionally, Part II will consider the situation
through the pharmaceutical companies' perspective. Part III
will discuss international intellectual property law as adminis-
tered by the World Trade Organization through the Trade-Re-
lated Aspects of Intellectual Property Rights Agreement
(TRIPS) and the Doha Declaration on TRIPS and Public Health.
It will also discuss Thailand's Patent law and how it deals with
compulsory licenses. Part IV will argue that Thailand's actions
are misguided and in the long run will actually decrease the
availability of affordable medications in developing countries,
as well as scare off the foreign investors that so many develop-
ing countries desperately need. This article will also argue that
if drug manufacturers are forced to relinquish their patent
rights and to give away their products to developing countries,
then not only will medical innovation suffer, but U.S patients
will have to pay higher drug costs to support pharmaceutical
R&D. This section suggests that, although the flexibility of
TRIPS that allows for compulsory licenses is desirable in aiding
developing countries in need of emergency access to medication,
it needs to be more narrowly interpreted in order to prevent
abuse.
II. THAILAND VS. THE PHARMACEUTICAL INDUSTRY
A. The Thai Dilemma
In 2004, Thailand introduced a government funded health-
care plan to provide basic health care to all Thai citizens. 17 Ad-
ditionally, at Thailand's 15th International AIDS Conference in
Bangkok, the government pledged to include HIV/AIDS pa-
tients under the umbrella of its new health care plan.' 8 Provid-
ing free medication to HIV/AIDS patients is an admirable
objective and with a growing economy and a new focus on
health care, it appeared to be an attainable goal. Thailand has a
relatively strong gross domestic product (GDP), 19 current ac-
17 See Hookway & Zamiska, supra note 8.
18 Id.
19 Thailand's GDP (PPP) is $515.3 billion and $8090 per capita. TIM KANE, ET
AL., INDEX FOR ECONOMIC FREEDOM 363 (The Heritage Foundation & Wall St. J.
eds., 2007), available at http://www.heritage.org/index/.
238 [Vol. 19:233
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count surplus,20 and impressive export performance. 21 With an
increase in budgetary resources for health care, help from inter-
national aid agencies, and already discounted drug prices, 22
hopes were high that the government would be able to provide
medicine to the estimated 10,000 Thai's23 who require second-
line treatment.24
When Thailand's armed forces took power in a military
coup in September 2006, pro-business Prime Minister Thaksin
Shinawatra was exiled and the new military installed regime
chose to break pharmaceutical patents rather than use govern-
ment money to fund health care for HIV/AIDS patients. 25 Dr.
Mongkol na Songkhla, a former senior bureaucrat, was ap-
pointed Thailand's new health minister and quickly took the op-
portunity to seize the patent rights of several U.S. drug
manufacturers. 26 Dr. Mongkol claims that Thailand previously
20 Thailand's current account surplus is 1.6% of its GDP in 2006. World
Bank, Thailand Economic Monitor, http://siteresources.worldbank.org/INT
THAILAND/Resources/Economic-Monitor/2007april-tem overview.pdf (last vis-
ited Oct. 23, 2007).
21 Thailand's exports topped over $130 billion worth of products in 2006. Id.
It is the world's number one exporter of rice, exporting 6.5 million tons of milled
rice annually. Other major exports include "textiles and footwear, fishery products
... rubber, jewelry, automobiles, computers and electrical appliances." Central
Intelligence Agency, The World Fact Book 2007, https://www.cia.gov/library/
publications/the-world-factbook/geos/th.html (last visited Apr. 27, 2008).
22 In general, pharmaceutical companies charge different prices for medica-
tion in different countries depending on the average income of the individual coun-
try. Id. Many times medicine is given away or sold at a discount price. Associated
Press, U.S. Firm, Thailand Face-off in HIV Drug Patent Feud, EAST VALLEY
SCOTTSDALE TRIBUNE, June 11, 2007, available at http://www.eastvalleytribune.
comlstory/91345.
23 Songphol Suckchan, Editorial, Thailand's Compulsory Drug Licensing,
WALL ST. J., May 16, 2007, at A19 (Thailand's Director of Press Division defending
Thailand's decision to issue compulsory licenses).
24 The WHO recommends that one particular combination of ARVs be taken
for most people when they begin HIV treatment - this is the first-line treatment.
See World Health Organization, Antiretroviral Therapy for HIV Infection in
Adults and Adolescents in Resource-limited Settings: Towards Universal Access -
Recommendations for a Public Health Approach (2006), http://www.who.int/hiv/
pub/guidelines/artadultguidelines.pdf When the first-line treatment becomes inef-
fective or resistant, a new combination of drugs is taken, which has been dubbed a
second-line treatment. Id. The new second-line treatment will ideally include at
least three new drugs with at least one from a new class to increase the likelihood
of treatment success and to decrease the chance of cross resistance. Id.
25 BBC News, Thai Government Hires PR Company, BBC NEws, Apr. 30,
2007, http://news.bbc.co.uk/2/hi/asia-pacific/6608181.stm
26 See Hookway & Zamiska, supra note 8.
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attempted to negotiate with pharmaceutical companies for
lower cost drugs.2 7 Whatever the truth may be, the fact remains
that just prior to the issuance of the first compulsory license the
pharmaceutical companies were at the table willing to negoti-
ate. Nevertheless, the Thai government proceeded to issue not
one, but three compulsory licenses. 28
It is easy for the new Ministry of Public Health to impose
such a radical agenda because as part of an unelected military
installed government, they are not accountable to anyone. The
health ministers of the current interim government are com-
fortable imposing their agenda and letting the next elected gov-
ernment clean up the mess. Thailand's latest policies will
garner public favor but the government has obviously not con-
sidered the long term consequences that will ultimately harm
its citizens and its relationship with foreign investors, a rela-
tionship which was partly based on Thailand's past respect for
patents.
Thailand's new government policies do not agree with the
country's strong history of supporting intellectual property
rights. In fact, Thailand's King, His Majesty Bhumibol Aduly-
adej, just recently received the World Intellectual Property Or-
ganization's (WIPO) Global Leaders Award, "in recognition of
his remarkable contribution to intellectual property both as an
inventor and as an active proponent of intellectual property as a
tool for development. '29 It is difficult to reconcile Thailand's
new stance with the country's past progressive pro-intellectual
property policies and initiatives.
27 Id.
28 Abbott v. Thailand Fact Sheet, www.amsa.org/global/aids/AbbottThailand
FactSheet.doc (last visited Aug. 19, 2008).
29 The Global Leaders Award is WIPO's most prestigious award to recognize
world leader's efforts to support intellectual property and to promote development.
See World Intellectual Property Organization, King of Thailand to Receive WIPO's
First Global Leaders Award (Jan. 29, 2007), available at http://www.wipo.intl
pressroom/en/articles/2007/article_0004.html. King Bhumibol Adulyadej is an in-
ventor and has been a strong proponent of intellectual property rights. Id. He
owns over 20 patents and 19 trademarks, many of which have been used to aid
Thai communities. Id.
240 [Vol. 19:233
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1. What Has Happened to Date
The first casualty was Merck & Co.'s AIDS drug
efavirenz. 30 On November 29, 2006, the Thai government sent a
letter to Merck informing the company that Thailand was plan-
ning on breaking Merck's patent and importing a generic ver-
sion of efavirenz.3 1 In February 2007, Merck announced that it
would reduce the price of efavirenz by 14.5% in countries that
have especially serious AIDS problems.32 This would include
Thailand. By dropping the price down to 65 cents per day per
patient, Merck would make no profit.33 Despite the fact that
Merck had announced it was committed to reaching a negoti-
ated agreement, the Thai government proceeded to import cop-
ies of efavirenz made by India's Ranbaxy Laboratories Ltd.34
Abbott Laboratories was the next to be hit. Two months af-
ter Merck, Abbott received a similar letter from the Thai gov-
ernment regarding the AIDS drug Kaletra. 35 Abbott had
already cut the yearly price of Kaletra down to $2200 per year36
in several developing countries, including Thailand, and were
prepared to further reduce the price if need be. A meeting had
been scheduled between Abbott and the Thai Ministry of Health
to discuss such price negotiations, but once the compulsory li-
cense notice had been sent, the Ministry cancelled the meet-
ing.3 7 According to an Abbott spokesperson, Abbott was told by
the Ministry that the compulsory license would stand regard-
less of what Kaletra was priced at.38
30 See Letter from the Department of Disease Control to Merck Sharp and
Dohme, 10 BURNING ISSUES, supra note 2, at 47-48
31 Letter from the Department of Disease Control to Merck Sharp and Dohme,
10 BURNING ISSUES, supra note 2, at 47-48.
32 See Hookway & Zamiska, supra note 8.
33 Id.
34 Id.
35 Letter from the Department of Disease Control to Merck Sharp and Dohme,
10 BURNING ISSUES, supra note 2, at 49-50.
36 Abbott reduced the annual price of Kaletra from a cost of $7500 in the U.S
to $2200. The Henry J. Kaiser Family Foundation, Drug Access: Abbott to Reduce
Cost of Kaletra in Thailand, Other Developing Countries (Apr. 11, 2007), http:/!
www.kaisemetwork.org/daily-reports/rep-index.cfm?hint=l&DRID=44162. Ab-
bott already provides the drug for $500 annually in 69 of the least developed coun-
tries, including all of Africa. Id.
37 See Hookway & Zamiska, supra note 8.
38 Id.
2007]
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After Dr. Mongkol announced that Thailand was consider-
ing breaking the patents of 11 more drugs, 39 Abbott retaliated.
Abbott pulled the applications for seven medications it had been
seeking approval of through Thailand's Food and Drug Admin-
istration.40 The applications included drugs for arthritis, high
blood pressure, and other conditions. 41 It also included an appli-
cation for the new AIDS drug Aluvia®, which contains the same
active ingredient as Kaletra but does not need to be
refrigerated. 42
As a result of its actions, Abbott was hit with a deluge of
backlash from non-governmental organizations (NGOs) across
the world. In April, after discussions with the World Health Or-
ganization (WHO), Abbott was willing to compromise. 43 Abbott
agreed to sell Kaletra to more than 40 developing countries, in-
cluding Thailand, for $1000 per patient annually,44 so long as
its patent was kept intact. Abbott has also said it will reinstate
its Aluvia application and sell the drug for $1000 per patient
per year if Thailand agrees to respect its patent.45 At this point
the fate of the other six applications is unresolved; Abbott is not
giving in but has shown it is willing to negotiate with the Thai
government.46
39 After this announcement, Thai officials affirmed that they reserved the
right to issue compulsory licenses but had no immediate plans to do so. Id.
40 Id.
41 Id.
42 In addition to Aluvia®, Abbott pulled applications for Brufen® (ibuprofen),
Abbotic® (clarithromycin), Clivarine® (heparin), Humira® (adalimumab), Tarka®
(trandolapril/verapamil HCL ER), and Wemplar® (paricalcitol). Sean Flynn,
Thailand's Lawful Compulsory Licensing and Abbott's Anticompetitive Response,
(Apr. 26, 2007), at 2 n.7, available at http://www.wcl.american.edu/pijip/
documents/Thailandreport426.2_001.pdf?rd=1 (discussing how Thailand's issu-
ance of compulsory licenses is legal under Thai law as well as under the WTO
TRIPS agreement and how Abbott's actions violate Thailand's Competition Act).
43 Press Release, Abbott Laboratories, Abbott Agrees with WHO Director-
General to Expand Access to Kaletra/Aluvia (Apr. 10, 2007), available at http://
www.abbott.comlglobal/url/pressRelease/enUS/60.5:5/PressRelease_0442.htm.
44 This price is lower than any generic price available and is approximately
55% less than the current average price in developing and least developing coun-
tries. Id.
45 See id. at 1.
46 See Hookway & Zamiska, supra note 8.
[Vol. 19:233
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In February, Thailand issued a third compulsory license.47
This one for the blood-thinning drug Plavix, developed by Sa-
nofi-Aventis of France and marketed by the U.S. company Bris-
tol-Meyers Squibb.48 This compulsory license has drawn more
criticism than the previous two because Plavix is a preventative
drug.49 It weakens Thailand's stance because, although heart
disease is a serious health concern, there are many more afford-
able and off-patent alternatives available. 50 Thus, the compul-
sory license for Plavix demonstrates the new Thai government's
contempt for patents rather than a genuine effort to relieve a
public health crisis.
2. What Other Options Does Thailand Have?
If the Thai government genuinely wants to protect its peo-
ple and fight HIV/AIDS, it has many other options that would
not invite such detrimental consequences. Thailand's decision
to issue compulsory licenses is short sighted and will likely re-
sult in more harm than good. Moreover, treating the symptoms
of AIDS is only a band-aid solution and will not fix the underly-
ing problems that have resulted in so many people contracting
HIV and having inadequate access to medicine. For Thailand's
health care goals to have any chance of success it needs to spend
more money on its health care policies, discontinue the use of
substandard generic drugs which are causing resistance, and fo-
cus more on prevention.
a. Thailand's Health Care Expenditures
The U.N. estimates that as of 2006, there are 39.5 million
people living with HIV worldwide.5 1 A disproportionate amount
47 Third World Network, Thailand to Import Plavix Generics from India,
THIRD WORLD NETWORK INFO SERVICE ON INTELLECTUAL PROPERTY ISSUES (Aug.
29, 2007), http://www.twnside.org.sg/title2/intellectual-property/info.service/twn.
ipr.info.080701.htm.
48 Letter from the Permanent Secretary Office to Sanofi-Synthe'labo (Thai-
land) Ltd., 10 BURNING ISSUES, supra note 2, at 51-52.
49 See id.
50 Drugs in Thailand: The Government Should Take Care About Ripping Up
Patents, FIN. TIMES (London), Jan. 31, 2007, at 14.
51 U.N. Programme on HIV/AIDS & World Health Organization, UN!WHO
AIDS Epidemic Update: December 2006, at 1, UNAIDS/06.29E (2006), available at
http://data.unaids.org/pub/EPiReport/2006/2006-EpiUpdateen.pdf (last visted
Apr. 27, 2008).
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of those living with HIV are in developing and least developed
countries, particularly African countries. The UN and WHO es-
timate that there are 580,000 Thais living with HIV, a preva-
lence rate of 1.4%.52
Despite Thailand's laudable intention to support a univer-
sal health care system for its citizens, the government spends
relatively little on health care.53 Thailand's GDP is ranked in
the top 10% of wealthiest countries in the world,54 yet it spends
a total of only 3.5% of its GDP on health care.55 This is far less
than even much poorer countries such as Cambodia and Leba-
non who spend 12% and 11.6% on health care respectively. 56
Thailand claims that healthcare for its citizens is a top pri-
ority, yet instead of directing state funds towards public health,
the newly installed government has approved a $3.2 billion dol-
lar military budget, an almost fifty percent increase from
52 Id. at 32.
53 But see Sukchan, supra note 23.
54 Letter from Kenneth L. Adelman to Members of Congress (May 9, 2007) (on
file with author), available at http://usaforinnovation.org/images/2007_adelman
letter.pdf; PhRMA Meets with Thai Health Minister, supra note 16 (Thailand is
the worlds 21st largest economy out of more than 200).
55 World Bank, Health Nutrition Population Stats Thailand, http://devdata.
worldbank. org/hnpstats/HNPSummary/country Data/GetShowData. asp?sCtry=
THA,Thailand (last visited Sept. 4, 2007). Notwithstanding its very modest health
care expenditures, Thailand still reaps a high return on its investment. Overall
Thailand is a healthy country. Two important indicators for the health of a nation
are its under-5 mortality rate and its maternal mortality rate. Thailand's is 21 per
1000 live births and 44 per 100,000 live births respectively. World Health Organi-
zation, Mortality Country Fact Sheet 2006, http://www.who.int/whosis/mort/
profiles/mortsearo tha thailand.pdf. The average life expectancy for men and
women is 70 years. Id. See also JEREMIAH NORRIS, THE UNRAVELLING OF COMPUL-
SORY LICENSES: EVIDENCE FROM THAILAND AND INDIA 3 (Int'l Policy Press 2007),
available at http://www.fightingdiseases.orglpdf/unravelling-ofCLs-norris.pdf
(low rates of child and maternal mortality rates and the high life expectancy indi-
cate Thailand is shifting from relatively inexpensive parasitic and infectious dis-
eases to more costly chronic disorders); World Bank, Thailand Data Profile, http:l/
devdata.worldbank.org/external/CPProfile.asp?PTYPE=CP&CCODE=THA (last
visited Sept.4, 2007).
56 World Health Organization, Tough Choices: Investing in Health for Devel-
opment: Experiences from the Follow-up to the Commission on Macroeconomics and
Health elec. annex C (Health Expenditure Trends in Selected Countries) (Geneva
2006), at 2, available at http://www.who.int/macrohealth/documents/Electronic_
Annex C.pdf; World Bank, Health Nutrition Population Stats Lebanon, http://
devdata.worldbank.org/hnpstats/HNPSummary/countryData/GetShow Data.asp?
sCtry=LBN,Lebanon (last visited Sept. 4, 2007).
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2006.5 7 This new budget does not include allocations for new
arms, which will be funded by diverting money from "low prior-
ity projects."58 The military junta has also formed its own
14,000-strong security force at a cost of an additional $15 mil-
lion outside the $3.2 billion budget.5 9 The inefficiencies and bu-
reaucracies of the Thai military are astounding. 60 About two-
thirds of Thailand's military spending pays for the salaries of
hundreds of desk bound high-ranking officers whose job de-
scriptions are ambiguous at best.6 1 Such a top-heavy structure
leaves little money for such things as soldiers' salaries, arms,
training, and upgrades which have to be funded from else-
where. With such a system in place it is no wonder that there
are little resources left over for health care.
b. Thailand Created a Need for Patented Drugs by
Using Substandard Generic Drugs that have
Led to Resistant Strains of AIDS
Unlike many developing countries, Thailand has it own
pharmaceutical manufacturing facilities. The state-owned and
historically corrupt 62 Government Pharmaceutical Organiza-
57 $3.2 billion USD Budget Approved for Thai Military Spending, XINHUA
GENERAL NEWS SERVICE, Dec. 8, 2006, available at http://news3.xinhuanet.com/
english/2006-12/11/content_5470335.htm.
58 Id.
59 Winners and Losers Six Months After Thai Coup, AGENCE FRANCE PRESSE,
March 18, 2007, cited in Thailand's Military is Sucking Money Away from Public
Health, USA FOR INNOVATION, April 26, 2007, http://usaforinnovation.org/news/dis-
play-article.cfm?ID=24.
60 Id.
61 Editorial, Military Now Has to Shape Up, THE NATION (THAILAND), Dec. 8,
2007, available at http://www.nationmultimedia.com/2006/12/08/opinion/opinion-
30021038.php.
62 In 2002, Auditor-General Jaruvan Maintaka issued a report saying the
GPO sold about 60% of its medical products to government agencies at above mar-
ket prices. Daniele Ten Kate, Safe at Any Cost?, ASIA SENTINEL (HONG KONG), Jan.
24, 2007, available at http://www.asiasentinel.com/index.php?option=com-content
&task=view&id=351&Itemid=34. In some cases, products were marked up 1,000
percent. Id. Jaruvan alleged that the purchase of drugs through GPO has many
faults and they provide officials with the chance to reap personal benefits. Id. Ac-
cording to Anuthin Charnveerakul, the deputy public health minister under Thas-
kin, in 2003, the GPO made a net profit of 624.2 million baht on revenues of 3.7
billion baht. Id. A year later, revenues topped 4 billion baht, and rose to five bil-
lion in 2005. Profits for the GPO topped one billion baht in 2005. Id. Anuthin has
publicly criticized the GPO for spending a mere 19 million baht, just two percent of
net profit, on research and development. Id. The report said that the GPO,
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tion (GPO) has been the main supplier of a generic triple combi-
nation antiretroviral (ARV)63 drug called GPO-Vir. 64 In 2002,
the Global Fund to Fight HIV/AIDS granted the GPO $133 mil-
lion to upgrade its plant to meet international quality stan-
dards for GPO-Vir. 65 However, the GPO continually failed to
meet WHO standards and in 2006, the Fund withdrew the
money remaining from its donation. 66 After four years of testing
GPO-Vir, the drug still has not been listed on the WHO's pre-
qualification program.67 Dr. Lembit Rago, coordinator for
WHO's quality assurance and safety program, stated that,
"[dirugs that are not WHO pre-qualified may not directly kill
people, but they could foster resistance to AIDS drugs."6 8 Since
dubbed the "skimming profits" agency by cynical Thai observers, pilfered about
486 million baht, or about $13.3 million, from government coffers each year from
1998 to 2002. Id.
63 National Institute of Allergy and Infectious Disease, Treatment of HIV In-
fection, http://www.niaid.nih.gov/factsheets/treat-hiv.htm (last visited Oct. 29,
2007). ARVs are drugs used to fight retroviruses, specifically HIV. Id. ARVs are
only a treatment used to suppress HIV levels, not a cure. There are three major
classes of ARVs. Id. The first are reverse trascriptase inhibitors; this type of ARV
interferes with reverse transcription, a critical step in the HIV life cycle. Id. Sec-
ondly, there are Protease Inhibitors which "interfere with the protease enzyme
that HIV uses to produce infectious viral particles." Id. Thirdly, there are Fusion
Inhibitors which interfere with the virus' ability to fuse with the cellular mem-
brane, thereby blocking entry into the host cell. Id. As HIV reproduces itself, dif-
ferent strains of the virus emerge, some that are resistant to antiretroviral drugs.
Therefore, doctors recommend patients infected with HIV take a combination of
antiretroviral drugs known as highly active antiretroviral treatment (HAART). Id.
This strategy, which typically combines drugs from at least two different classes of
antiretroviral drugs, has been shown to effectively suppress the virus when used
properly. Id.
64 See Thai Government Scales Up Antiretroviral Treatment Efforts (October
2003) , available at http://www.amfar.org/cgi-bin/iowa/asia/news/?record=17.
65 Daniel Ten Kate, Safe at Any Cost?, ASIA SENTINAL, Jan. 24, 2007, available
at http://www.asiasentinel.com/index.php?Itemid=34&id=351&option=com-
content&task=view.
66 Roger Bate, Thailand and the Drug Patent Wars, AMERICAN ENTERPRISE
INSTITUTE FOR PUBLIC POLICY RESEARCH (Apr. 3, 2007), http://www.aei.org/docLib/
20070404_HPO.pdf.
67 See Norris, supra note 55, at 4.
68 Id. Sadly there have been deaths related to governments producing medica-
tions without adhering to international standards. Id. In Panama, a cough syrup
produced by a government run manufacturer was found to contain diethylene gly-
col, a toxic chemical used in anti-freeze and paint. Id. Approximately 30 people
died from the cough syrup and many more were hospitalized. See Kate, supra note
62. Between 1995 and 1996 there were a string of child deaths in Haiti. See Ste-
phanie Barbosa, Implementation of the Doha Declaration: Its Impact on American
Pharmaceuticals, 36 RUTGERS L.J. 205 (2004) at 227. Again investigators found
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2002, WHO has recommended that GPO-Vir not be sold outside
Thailand because of the GPO's failure to prove
bioequivalence. 69
In 2005, the drug's efficacy came into question when a
Mahidol University study found that resistance to GPO-Vir had
grown radically in the past few years and is only expected to get
worse. 70 Because of the increased rate of resistance, more peo-
ple must switch to more expensive patented medications for ef-
fective treatment. The NGO Medecins Sans Frontieres (MSF),71
one of Thailand's most vocal supporters in the issuance of com-
pulsory licenses, has also been complicit in the increased resis-
tance due to GPO-Vir. Despite documented drug resistance and
WHO admonitions, MSF continues to distribute the drug to pa-
tients in Thailand, Cambodia, and Burma.72
It is not yet clear whether the GPO will manufacture
efavirenz, Kaletra, and Plavix in its factory that still has not
met WHO standards. GPO officials announced they plan to
start local production this year, which is a minimum of two
years before the construction could be completed on a new pro-
duction facility that meets WHO standards. 73 If Thailand pro-
duces the drugs in a factory that does not meet international
standards, the results are likely to cause more harm than good
to the thousands of HIV/AIDS patients in need of medication.
c. HIV Prevention is the Key
To defeat HIV/AIDS, the focus should be on prevention, not
just treatment. Throughout the epidemic, across the world, pre-
vention has been the best defense against HIV/AIDS. If coun-
tries cannot afford to treat the people who currently have HIV/
diethylene glycol in the locally manufactured acetaminophen syrup. Id. In 1998,
200 women reported unwanted pregnancies after taking Brazilian manufactured
birth control pills that contained wheat flour instead of the active ingredient. Id.
69 Norris, supra note 55, at 4.
70 Arthit Khwankhom, HIV Drugs Losing Their Power, THE NATION (THAI-
LAND), July 19, 2005, available at http://www.nationmultimedia.com/2005/07/15/
headlines/index.php?news=headlines_18039782.html. But see Kate supra note 62
(stating that both the GPO and MSF disagree that GPO-Vir causes resistance in
AIDS. MSF believes there are other reasons for the resistance and the GPO claims
that the drug is of the same quality of other WHO approved drugs).
71 Also known as "Doctors Without Borders" in English.
72 See Kate, supra note 62.
73 Id.
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AIDS they are certainly not going to be able to treat future
patients.
i. Regulation of Thailand's Widespread Sex
Trade
According to Dr. Edward C. Green, a renowned Harvard so-
cial scientist, most cases of HIV are contracted through sex, and
"multi-partnering" drives epidemics. 74 There are different types
of epidemics. Generalized epidemics 75 are primarily spread
through heterosexual sex. However, in countries such as the
U.S. and Thailand, with lower HIV prevalence, HIV transmis-
sion occurs primarily within core transmitter groups such as
prostitutes, men who have sex with men, and IV drug users. 76
In Thailand prostitutes are the primary core transmitter
group. 77
Thailand is considered the capital of the sex-trade indus-
try. 78 It is estimated that there are over 300,000 women and
74 Kate Hendricks & Patricia Thickstun, Thailand's 100% Condom Use Pol-
icy: Success is in the Eye of the Beholder 2 (Medical Institute for Sexual Health
Technical Paper No. MISHIMCHB/TP-20050728, July 28, 2005), available at http:/
/www.medinstitute.org/includes/downloads/MCHBTP20050728.pdf.
75 Generalized epidemics are defined as epidemics in which HIV prevalence is
consistently greater than 1% in pregnant women. Id. at 2.
76 Id.
77 Id.
78 ASIA WATCH & THE WOMEN'S RIGHTS PROJECT, A MODERN FORM OF SLAV-
ERY: TRAFFICKING OF BURMESE WOMEN AND GIRLS INTO BROTHELS IN THAILAND 2
(Human Rights Watch 1993), available at http://www.hrw.org/reports/1993/
thailand/ [hereinafter ASIA WATCH & THE WOMEN'S RIGHTS PROJECT]:
[L]in Lin was thirteen years old when she was recruited by an agent for
work in Thailand. Her father took $480 from the agent with the under-
standing that his daughter would pay the loan back out of her earnings.
The agent took "Lin Lin" to Bangkok, and three days later she was taken
to the Ran Dee Prom Brothel. "Lin Lin" did not know what was going on
until a man came into her room and started touching her breasts and body
and then forced her to have sex. For the next two years, "Lin Lin" worked
in various parts of Thailand in four different brothels, all but one owned
by the same family. The owners told her she would have to keep working
until she paid off her father's debt. Her clients, who often included police,
paid the owner $4 each time. If she refused a client's demands, she was
slapped and threatened by the owner. She worked everyday except for the
two days off each month she was allowed for her menstrual period. Once
she had to borrow money to pay for medicine to treat a painful vaginal
infection. This amount was added to her debt. On January 18, 1993 the
Crime Suppression Division of the Thai police raided the brothel in which
"Lin Lin" worked, and she was taken to a shelter run by a local non-gov-
16http://digitalcommons.pace.edu/pilr/vol19/iss2/5
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children being exploited across Southeast Asia.79 Some of the
workers are orphans, others are sold off by their families, while
some are outright kidnapped.80 According to the Chulalongkorn
University Political Economy Centre in Bangkok, Thailand's
sex-trade generates annual revenues of over U.S. $4 billion.81
Yet the government does not recognize the trade, putting this
lucrative business in an economic and legal twilight zone. Fur-
ther blurring the line, Thai commerce laws sanction sex work as
a "personal service," notwithstanding the fact it has been illegal
under anti-prostitution laws since 1960.82 Thus the law ac-
ernmental organization. She was fifteen years old, had spent over two
years of her young life in compulsory prostitution, and tested positive for
the human immunodeficiency virus or HIV.
Id.
79 Anthony C. LoBaido, Sex-trade Flourishes in Thailand, WORLDNETDAILY,
Feb. 3, 2002, available at http://www.worldnetdaily.com/news/article.asp?
ARTICLEID=26296. This is a conservative estimate; some NGOs estimate there
are 800,000 to two million prostitutes currently working in Thailand. ASIA WATCH
& THE WOMEN'S RIGHTS PROJECT, supra note 78, at 1.
80 Anthony C. LoBaido, Sex-trade Flourishes in Thailand, WORLDNETDAILY,
Feb. 3, 2002, available at http://www.worldnetdaily.com/news/article.asp?
ARTICLEID=26296.
81 Betty Rogers, Bitter Harvest, Ms. MAGAZINE, Oct. 1999, available at http://
www.msmagazine.com/oct99/bitterharvest.asp.
82 ASIA WATCH & THE WOMEN'S RIGHTS PROJECT, supra note 78, at 12. After the
abolition of slavery in 1905 by King Rama V, prostitution in Thailand rapidly in-
creased as former slaves were drawn into the sex trade. Id. Prostitution was legal
from 1905 to 1960 and was regulated by the Control and Prevention of Venereal
Disease Act of 1909. Id. The Act allowed the government to control the sex trade by
establishing a system of licensing and fees. Id. Additionally, the Act required pros-
titutes to be "free of infectious disease." Id. In 1928, the Thai government passed
an Anti-Trafficking Act which expressly prohibited the trafficking of women and
girls for the purpose of having sexual intercourse. Id. at 13. Prostitution itself did
not become criminalized until 1960 when the government passed the Suppression
of Prostitution Act which is still in effect today. Id. In 1966, the government intro-
duced the Entertainment Places Act, which regulated nightclubs, dance halls,
bars, and places for baths and massages. Id. at 14. The Entertainment Act coin-
cided with a greater presence of American soldiers in Thailand. Id. The U.S. estab-
lished military bases in Thailand and allowed soldiers stationed in Vietnam to
visit Thailand for rest and relaxation. See id. at 20-24. In November 2003, Thai-
land proposed to again legalize prostitution. See Asociated Press, Thailand Holds
Debate on Legalizing Prostitution, TAIPEI TIMES, Nov. 28, 2003, available at http://
www.taipeitimes.com/News/world/archives/2003/11/28/2003077555. The govern-
ment claimed that if legalized, prostitutes would receive health care, social ser-
vices and protection from abuse. Id. Legalization would also help ferret out
corruption among police, politicians, and business owners. Legalizing prostitution
would also allow the government to tax the $4.3 billion industry, creating a boost
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knowledges the economic advantages of prostitution while effec-
tively making sex-workers criminals.8 3
For centuries, Thai men have been visiting brothels.8 4 Pros-
titution has long been an accepted form of entertainment that
wives expect and tolerate and men introduce their sons to.85 Ac-
cording to a Ministry of Public Health study, nearly three
quarters of all Thai males visit prostitutes on a regular basis
and that roughly half of all teenage boys are initiated into sex-
ual activity by prostitutes.8 6
Until recently, the Thai government seemed to be indiffer-
ent to the health dangers posed by the sex-trade industry. It
was the spread of HIV that finally spurred the government to
take action. In the early 1990s the government began an AIDS
prevention and education campaign.8 7 Even then, many brothel
owners refused to encourage condom use, because those that did
lost business. As a result, the 100% condom program was im-
plemented and businesses that refused to comply risked govern-
ment closure.88
The success of the government's program is debatable. At
first look it seems as though the increase in availability and use
of condoms in the sex trade decreased the spread of HIV.8 9
However, upon closer look this may not be completely accurate.
Although the rate of HIV infection decreased dramatically
among Thai military conscripts between 1993 and 1999,90 HIV
infection has actually increased among the general adult popu-
lation. The program has had little effect on the spread of HIV
between male customers of prostitutes and their regular sex
for the Thai economy. Id.; See also CNN.com, Thailand Debate Sex Trade (Nov. 27,
2003), http://www.cnn.com/2003/WORLD/asiapcf/southeast/11/27/thailand.sex.ap.
83 See Rogers, supra note 81.
84 See Donald Wilson and David Henley, Prostitution in Thailand: Facing
Hard Facts, BANGKOK POST, December 25, 1994, available at http://www.Hartford-
hwp.com/archives/54/072.html.
85 Betty Rogers, Bitter Harvest, Ms. MAGAZINE, October 1999, available at
http://www.msmagazine.com/oct99/bitterharvest. asp.
86 See Rogers, supra note 81.
87 See ASIA WATCH & THE WOMEN'S RIGHTS PROJECT, supra note 78, at 25.
88 See Hendricks & Thickstun, supra note 74, at 3.
89 Id.
90 The rate of HIV infection among Thai military personnel decreased from
3.7% in 1993 to approximately 1% in 1999. Id. at 3.
[Vol. 19:233
18http://digitalcommons.pace.edu/pilr/vol19/iss2/5
THAILAND'S AIDS EPIDEMIC
partners (wife or girlfriend).91 Overall, the infection rates
among prostitutes first increased and then decreased, but still
remain high.92 Studies have shown that Thai female sex work-
ers requested condom use 63% of the time, but overall condom
use was only 51%. Condom use differs by patrons' country of
origin. Westerners use condoms 76% of the time, foreign Asians
52%, and native Thai men only 27%. 93 These results are signifi-
cantly less than the goal of 100% condom use in Thai brothels. 94
Clearly Thailand's 100% condom program alone is not the
answer to curb the spread of HIV. The best solution would be to
abolish the sex trade industry completely but because of eco-
nomic reasons this is probably unlikely. If the government is
going to allow the sex trade to continue it should at the very
least closely regulate the industry. The government needs to be
able to enforce the 100% condom program and should mandate
that sex workers be tested for HIV and other STDs on a regular
basis.
ii. Education as a Form of Prevention
One of the most important aspects of HIV prevention is ed-
ucation. To stop the spread of HIV it is important to not only
educate people about the disease itself but also about preven-
tion and treatment. One important aspect of prevention is con-
dom use. The public needs to be educated about and encouraged
to use condoms. The Thai government has done this to a certain
extent but because native Thai men are the least likely prosti-
tute patron (27%) to use a condom, public health initiatives
91 See U.N. Programme on HIV/AIDS & World Health Org., supra note 51, at
33.
92 One study found 5.5% of sex workers who began working before 1989 were
HIV infected, 8.0% of workers who began in 1990-1993 were infected, and 12.5% of
those who began work in 1994-1999 were infected. Peter H. Kilmarx, et al., Ser-
oprevalence of HIV Among Female Sex Workers in Bangkok: Evidence of Ongoing
Infection Risk After the "100% Condom Program" was Implemented, 21 J. Ac-
QUIRED IMMUNE DEFICIENCY SYNDROME 313 (1999) cited in Hendricks & Thickstun,
supra note 74, at 4.
93 Robert Buckingham and Edward Meister, Condom Utilization Among Fe-
male Sex Workers in Thailand: Assessing the Value of the Health Belief Model, 4
CALIFORNIA JOURNAL OF HEALTH PROMOTION 18 (2003), available at http://www.csu
chico.edu/cjhp/1/4/18-23-buckingham.pdf.
94 R.W. Buckingham, et al., Factors Associated with Condom Use Among
Brothel-based Female Sex Workers in Thailand, 17 AIDS CARE 640 (July 2005).
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need to especially target this group.95 The programs need to en-
courage Thai men to not only use condoms with prostitutes, but
also to use condoms with their regular partners if they are not
going to be monogamous. Part of the problem of the government
sponsored condom program is incorrect condom use. Method
failure accounts for decreased risk reduction even with consis-
tent use.96 Education programs should teach correct condom
use as well as inform people that condoms are never 100% effec-
tive. Additionally, other programs that educate people on and
promote monogamy and/or abstinence may help control the
spread of HIV.
B. The Pharmaceutical Companies
Over the last decade, 330 new medicines have become
available to patients. 97 These include medicines for some of the
most devastating and expensive diseases such as AIDS, cancer,
and heart disease. In addition, there are over 1,000 new medica-
tions in the R&D pipeline. 98 Economists estimate that new
medicines are responsible for approximately half of the increase
in life expectancy achieved over the past 15 years. 99 The eco-
nomic gains from medical innovation in the U.S. alone are esti-
mated at more than $500 billion per year. 100 Biotechnology and
pharmaceutical companies represent one of the most research-
intensive industries and U.S. companies are responsible for
most of these new drugs. 10 The reason there are such effective
drugs available to fight HIV/AIDS is because developed coun-
tries have the resources to invest in developing treatments and
have patent protection providing incentive to develop new
drugs.
95 Id. at 643.
96 See Hendricks & Thickstun, supra note 74, at 5.
97 Cost of Prescription Drugs, supra note 11, at 7.
98 Id.
99 See id. at 5.
100 Neil Masia, The Cost of Developing a New Drug, Jan. 2006, http://us
info.state.gov/products/pubs/intelprp/cost.htm (last visited Nov. 11, 2007).
101 COST OF PRESCRIPTION DRUGS, supra note 11, at 2.
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1. The Cost of Research and Development of New
Medicines
The cost of a new medication is more than the sum of its
ingredients. In 2006, U.S. Biotech and Pharmaceutical compa-
nies spent an all-time high of $55.2 billion on R&D. 102 The dis-
covery process, development, testing, and obtaining FDA
approval for a new medicine is a long and expensive process and
there are great risks that a promising line of research will not
work out. It takes an estimated 12 to 15 years and approxi-
mately $800 million to discover and develop a new drug 10 3 and
it costs an average of $1.2 billion to develop a biologic.' 0 4 On
average, only 0.0005% of compounds investigated ever make it
to clinical trials. 10 5 That is only five out of every 10,000 com-
pounds. Only one of those five will be approved for patient
use. 10 6 Revenues from that one successful drug have to cover
the costs for all of the compounds that do not pan out.10 7
A common misconception about pharmaceutical develop-
ment in the U.S. is that the government invents and funds re-
search for most new medicines. Many people believe that the
National Institute of Health (NIH), a tax-payer-funded research
institute, does most of the R&D work in developing new
medicines.108 The fact is the vast majority of medicines are de-
veloped by pharmaceutical research companies. 0 9 Pharmaceu-
tical companies spend far more on R&D than the NIH and are
responsible for the discovery and development of most new
medicines. The NIH spends just over half of what pharmaceuti-
cal companies spend on R&D. 110 The Government Accountabil-
102 Press Release, PhRMA, R&D Spending by U.S. Biopharmaceutical Compa-
nies Reaches a Record $55.2 Billion in 2006 (Feb. 12, 2007), available at http:/!
www.phrma.org/news-room/press-releases/r&d-spending-.by-u.s.-
biopharmaceutical-companiesjreaches a_record_$55.2_billionin_2006/.
103 COST OF PRESCRIPTION DRUGS, supra note 11, at 2.
104 A biologic is a medicine composed of molecules produced by a biological sys-
tem. PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA, PHARMACEUTI-
CAL INDUSTRY PROFILE 2007, 5 (Mar. 2007), http://www.phrma.org/files/Profile
%202007.pdf [hereinafter PHARMACEUTICAL PROFILE].
105 See id. at 6.
106 Id.
107 COST OF PRESCRIPTION DRUGS, supra note 11, at 2.
108 Id.
109 Id. at 8.
110 Id.
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ity Office (GAO) found that of the top 100 medicines purchased
by the Department of Defense (DOD) and the Department of
Veterans Affairs (VA), the government had licensing rights to
only six of those purchased by the DOD and only four of those
bought by the VA."1" Government and NIH funded academic
scientists contribute a great deal to advancing knowledge about
biology and disease, but it is more often the pharmaceutical
companies that translate the basic science into practical
medicines.
2. Cost of Drugs in Developed vs. Developing Countries
Many patented drugs are already sold to developing and
least developed countries at a highly discounted price. 112 One
example is Gilead Sciences Inc., which began offering its AIDS
drug Viread to 68 of the world's poorest countries at cost. 1 3 The
pharmaceutical company offered Viread to nations throughout
Africa, as well as to 15 other impoverished countries, for $1.30
per once-daily pill.1 14 A year's supply that would cost roughly
$4,300 per year in the U.S. costs only $475 annually in qualified
countries. 1 5 This is only one example of many, including the
discounted prices Abbott offered on Kaletra to developing coun-
tries and LDCs. 11 6 In general, treatment with ARVs cost be-
tween $350 to $1000 annually in most African countries. 117 This
is approximately 90% less than yearly treatment costs in the
U.S.""8 These discounted prices do not take into account the
millions of dollars worth of pharmaceuticals and medical equip-
111 Id.
112 See supra text accompanying note 21.
113 AIDS Drugs Will Be Offered in Poor Countries at Cost, April 4, 2003, http://
www.thebody.com/content/treattart29635.html.
114 Id.
115 Gilead Sciences Inc.: AIDS Drug Will be Offered in Poor Countries at Cost,
WALL ST. J., April 4, 2003, at C7 (stating that the lower price covers solely manu-
facturing and distribution costs).
116 See supra text accompanying note 31.
117 Michael Fleshman, Global AIDS Treatment Drive Takes Off, 19 AFRICA RE-
NEwAL 1, 8 (2005).
118 Amir Attaran & Lee Gillespie-White, Do Patents for Antiretroviral Drugs
Constrain Access to AIDS Treatment in Africa?, 286 JAMA 1886 (2001), available
at http://www.iipi.org/articles/antiretroviral-article.pdf.
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ment donated through pharmaceutical companies' philan-
thropic work.119
3. Philanthropy of the Pharmaceutical Industry
Pharmaceutical companies contribute money, medicine,
supplies, and expertise to many of the world's leading philan-
thropic organizations. 120 In 2003, the pharmaceutical industry
spent an estimated $1.4 to $2.1 billion' 2l on global health care.
This is more than the annual global health budgets of the WHO,
the World Bank, and many other humanitarian organiza-
tions. 122 The pharmaceutical industry's contribution to global
health accounts for "more than a third of the United States' to-
tal healthcare assistance to the developing world."123 One of the
main focuses of the pharmaceutical industry is implementing
long-term programs. Many of their programs are more than ten
years old and many involve long term goals requiring commit-
ments far into the future. Pharmaceutical industry programs
aimed at HIV/AIDS have grown from 24 programs in 2006 to 52
programs in 2007.124 Tens of millions of people living in over
100 developing and least developed countries have benefited
119 See PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA, HEALTH
CARE IN THE DEVELOPING WORLD 4 (2004), http://www.phrma.org/files/Global-
Partnerships_2004.pdf.
120 Id.
121 The discrepancy in estimates is due to data from two different studies.
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA, HEALTH CARE IN
THE DEVELOPING WORLD 4 (2004), http://www.phrma.org/files/GlobalPartnerships
_2004.pdf [hereinafter Health Care in the Developing World]. The study which
puts spending at $1.4 billion does not include the value of drug and in-kind dona-
tions made by as many as 24 non-PQMD (Partnership for Quality Medical Dona-
tions) pharmaceutical companies to non-PQMD nongovernmental organizations.
Nor does it account for donated medical care and other services by company em-
ployees. PQMD corporate members include Abbott Laboratories, BD, Boehringer
Ingelhein, Bristol-Meyers Squibb Company, GlaxoSmithKline, Johnson & John-
son, Merck & Co., Pfizer Inc., and Wyeth Pharmaceuticals. Humanitarian mem-
bers include AmeriCares, Catholic Medical Mission Board, Direct Relief
International, Heart to Heart International, Interchurch Medical Assistance, Inc.,
International Aid, MAP International, Mercy Ships, Northwest Medical Teams,
Project HOPE, U.S. Fund for UNICEF, and World Vision. Id. n.1.
122 This is more than the $1.37 billion spent by USAID and WHO each, the
$1.3 billion spent by UNICEF, the $1.03 billion spent by the World Bank, and the
$850 million spent by the European Union. Id.
123 Id.
124 G8 Summit, supra note 13, at 12.
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from the efforts and finances of the pharmaceutical industry. 125
The extent of programs that have been put into practice and the
money and resources that have been donated is overwhelming.
Thailand is one of many countries that has benefited from
the generosity of pharmaceutical companies. The list is long but
some examples include family planning and HIV/AIDS educa-
tion to teenagers and young adults, "Rainbow Camps" for HIV-
infected children, and hundreds of thousands of dollars in
donated ARV medicines through the Thai Red Cross. These are
just a few examples and do not represent the many non-medical
donations and programs. 126
125 HEALTH CARE IN THE DEVELOPING WORLD, supra note 121.
126 See HEALTH CARE IN THE DEVELOPING WORLD, supra note 121. Pharmacies
that have donated to and helped develop philanthropic programs in Thailand in-
clude: Abbott, AstraZeneca, Bristol-Meyers Squibb, GlaxoSmithKline, Johnson &
Johnson, Merck & Co., Inc., Pfizer, and Sanofi-Aventis. See generally HEALTH CARE
IN THE DEVELOPING WORLD, supra note 121; see generally PHARMACEUTICAL RE-
SEARCH AND MANUFACTURERS OF AMERICA, Pharmaceutical Corporate Philan-
thropy in Asia 1 (2007), available at http://www.phrma.org/files/Asia%20
Philanthropy%20brochure.pdf. In December 2004, donations of $85,000 were
made to the immediate relief efforts following the Asian Tsunami. PHARMACEUTI-
CAL RESEARCH AND MANUFACTURERS OF AMERICA, PHARMACEUTICAL CORPORATE
PHILANTHROPY IN ASIA 34 (2007), available at http://www.phrma.org/files/Asia%20
Philanthropy%20brochure.pdf. Hospitals and health centers in affected areas
have received $1.64 million in cash and medicines donated by Pfizer. Id. at 37.
Eight houses and community centers were rebuilt in Khao Lak, the worst hit area
in Thailand, through a $100,000 donation to the Reconstruction Project. Id. at 34.
In October 2006, pharmaceutical employees volunteered to participate in a govern-
ment initiative to plant a forest in southern Thailand to renew depleted mangrove
forests and protect the coastline and biodiversity. Id. at 35. With support from the
pharmaceutical industry the Population and Community Development Association
will provide family planning, HIV/AIDS and sex education for teenagers in 30
schools in Bangkok. Id. This initiative includes a camp to train teachers and stu-
dents to run programs, a mobile classroom, materials, hotlines, drop-in centers,
and web sites. Id. The pharmaceutical industry supports the Thai Red Cross ef-
forts to bring life skills and HIV/AIDS education to children and youth in Bangkok
slums. Id. One pharmaceutical company is working with the Raks Thai Founda-
tion which supports some 160 families in fishing communities in Krabi and Pang
Nga provinces, helping them rebuild their lives and livelihoods through a revolving
fund that enables families to purchase boats, engines, or fishing equipment. Id.
The funds are managed by the communities themselves and are part of the long-
term rehabilitation plan for their area. Id. A part of a $285,000 grant supports
rehabilitation activities relating to health and livelihood improvements, natural
and environmental management, emergency response and disaster risk manage-
ment, and social networking. Id. at 35-6. In 1997, with rural areas facing a severe
nursing shortage, the Rural Nursing Excellence Program was established. Id. at
36. The on-going program has awarded over 400 scholarships at 30 nursing col-
leges. Id. Approximately 250 students have graduated and are working in 120
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Although the pharmaceutical industry has become an easy
scapegoat for many groups to blame for high-priced drugs and
inaccessibility to medicine, it is clear that pharmaceutical com-
panies are doing more than their share of humanitarian work.
Pharmaceutical companies create life-saving drugs and despite
popular belief, they also do their share to help get those
hospitals and public health centers in 50 provinces. Id. The Life Skills Foundation
provides life skills education, training, and promotion for children and their fami-
lies affected by HIV/AIDS. Id. It emphasizes psychosocial development to help
reduce the stigma and discrimination associated with the disease. Id. The Foun-
dation has assisted 169 children and their families and has educated more than
1,600 non-affected children. Id. In 1998, the Enhancing Care Initiative was cre-
ated with a five year, $5 million grant from Merck. Id. It is a joint program of the
Harvard AIDS Institute and the Francois-Xavier Bagnound Center at the Harvard
School of Public Health; it works to improve the care of people living with HIV/
AIDS in resource limited settings in Thailand. Id. Merck also contributed $1.1
million to support a program jointly conducted by Chiang Mai University's Faculty
of Nursing and the Harvard AIDS Institute to improve HIV/AIDS healthcare ser-
vices. Id. at 37 Five Global Health Fellowships has also been established to work
on community-based projects with vulnerable populations at high risk for HIV/
AIDS. Id. Pa Tong Koh (PTK) has brought HIV/AIDS patients and non-infected
people together in almost 375 business partnerships for the purpose of reducing
stereotypes and breaking down social barriers. Id. PTK provides small business
loans through Population & Community Development Association since 2004 and
is considered a "Best Practice" by UNAIDS. Id. Pfizer teamed up with the Depart-
ment of Mental Health and the Ministry of Public Health to establish a Mental
Health Recovery Center and organized post traumatic stress syndrome confer-
ences for psychiatrists, psychologists, social workers, and nurses to deal with the
mental health effects of disaster trauma. Id. They also organized community out-
reach and mental health education to the children in the effected area. Id. Since
2003, 141 scholarships totaling $148,000 have been awarded to high school and
university students who have demonstrated academic performance and financial
need. Id. The aim is to encourage the study of science, medicine, pharmacy, or
public health. Id. Since 2004, Pfizer alone has conducted more than 40 global
clinical studies in Thailand in many therapeutic disease areas. Id. at 38. They
have also partnered with the Disease Controls Department, the Thai Food & Drug
Administration, public hospitals, medical science departments, and medical
schools to conduct "Good Clinical Practice" training for research physicians and
healthcare professionals involved in clinical research. Id. The Pfizer Thailand
Foundation has contributed $195,000 to train 800 physicians, nurses and counsel-
ors to provide medical and social care for HIV/AIDS patients. Id. On Thailand's
highly militarized borders with Burma, the Agency for Information and Mediation
for Children (AIM) provides support for refugee children affected by the conflict
with ethnic minorities. Id. With support from pharmaceutical companies, AIM
operates orphanages and schools and offers education in hygiene, medical care,
and vocational training for women. Id. These programs are only representative of
the pharmaceutical industries' work in Thailand, it does not include the many pro-
grams and donations made in other developing countries and LDCs.
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medicines to people that need them regardless of income or
status.
III. THE LAW: INTERNATIONAL PATENT RIGHTS
A. International Trade and Intellectual Property Law
The importance of patents has been recognized since the
13th century when, in an effort to spur the innovation of new
technologies, the Venetian Republic enacted legislation in 1474
which is considered to be the first true patent statute.12 7 Patent
traditions, carried over from England, were practiced early on
in many of the English colonies here in the United States and
soon found their way into our Constitution. 128 The U.S. Consti-
tution states that the purpose of patents are to, "promote the
progress of science and the useful arts, by securing for limited
times to authors and inventors the exclusive right to their re-
spective writings and discoveries. " 129 The purpose is not to pro-
mote monopolies and price control, as some argue. 130 Patents
are a trade off; patent holders disclose their invention in ex-
change for the right to exclude others from its use for a set pe-
riod of time.' 3 ' This trade off promotes scientific progress by
increasing the amount of knowledge available to the public. Ad-
ditionally, the prospect of obtaining a patent provides an incen-
tive to invest in research to create new innovations. 132 Strong
127 See Giulio Mandich, Venetian Patents (1450-1550), 30 J. PAT. OFF. SOC'Y
166 (1948).
128 See generally Edward C. Waltersceid, The Early Evolution of United States
Patent Law: Antecedents (Part I), 78 J. PATENT & TRADEMARK OFF. Soc'Y 615
(1996).
129 U.S. CONST. art. I, § 8, cl. 8.
130 See generally Brittany Whobrey, International Patent Law and Public
Health: Analyzing TRIPS' Effect on Access to Pharmaceuticals in Developing Coun-
tries, 45 BRANDEIS L.J. 623 (2007) (arguing that strong patent rights create monop-
olies and price controls of specific drugs).
131 See 35 U.S.C. §§ 111, 112 (2007). Under U.S. and international law, inven-
tors granted a patent may exclude others from its use for 20 years from the date
the patent application was filed. 35 U.S.C. § 154(a)(2) (2007); see Agreement on
Trade-Related Aspects of Intellectual Property Rights, Apr. 15, 1994, Marrakesh
Agreement Establishing the World Trade Organization, Annex 1C, Legal Instru-
ments - Results of the Uruguay Round, 33 I.L.M. 81 (1994) [hereinafter TRIPS
Agreement].
132 See Barbosa, supra note 68, at 216-32; see also John A. Harrelson, TRIPS,
Pharmaceutical Patents, and the HIVIAIDS Crisis: Finding the Proper Balance
Between Intellectual property Rights and Compassion, 7 WIDENER L. SYMP. 175,
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intellectual property rights are essential for the innovation and
development of new drugs. The United States has recognized
this and has been a staunch advocate of protecting intellectual
property rights at home and abroad, but as our economy has
become increasingly dependent on technology-based industries,
intellectual property rights have become an even higher priority
to U.S. policy makers and diplomats. 133
1. The World Trade Organization: A Global Nexus for
International Trade
The WTO is an international association designed to facili-
tate trade between its member nations. 34 The philosophy is
that free trade will result in greater economic growth. 135 The
WTO believes that, "liberal trade-policies-policies that allow
the unrestricted flow of goods and services-sharpen competi-
tion, motivate innovation, and breed success." 136
The WTO is the successor to the General Agreement on
Tariffs and Trade (GATT).137 GATT was established in 1947 as
part of an effort to promote global economic recovery after
World War 11.138 The newly created United Nations asked a
committee of 18 countries to draft a charter for the proposed
International Trade Organization (ITO).' 39 The charter was
adopted at the United Nations Conference on Trade and Em-
ployment at Havana; however, the agreement was never rati-
187-88 (2001) (highlighting the debate over the level of patent protection that
should be required for pharmaceuticals in developing and least developed
countries).
133 See Michael L. Doane, TRIPS and International Property Protection in an
Age of Advancing Technology, 9 AM. U. J. INT'L L. & POL'Y 465, 488 (1994) (discuss-
ing the impact that advancing technology has had in the arena of international
intellectual property law).
134 See World Trade Organization, http://www.WTO.org (last visited May 23,
2008).
135 Id.
136 World Trade Organization, Understanding the WTO: Basics, http://www.
wto.org/English/thewto-e/whatis_e/tif_e/fact3 e.htm (last visited May 23, 2008).
137 World Trade Organization, What is the WTO?, http://www.wto.org/english
thewto e/whatise/whatis e.htm (last visited Nov. 18, 2007).
138 The Roots of the WTO, http://www.econ.iastate.edu/classes/econ355/choi/
wtoroots.htm (last visited Aug. 19, 2008).
139 DANIEL GERVAIS, THE TRIPS AGREEMENT: DRArNG HISTORY AND ANALYSIS
3-4 (Sweet & Maxwell Ltd. 2d ed. 2003) (1998).
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fied. 140 As a result, the ITO never came into being and instead
GATT was born.141 GATT had very few provisions dealing with
intellectual property, and what it did have was woefully inade-
quate to deal with the emergence of technology over the next 50
years. 142 Towards the end of the century many industrialized
nations were pushing to establish new intellectual property
standards under GATT.143 When the Uruguay Round of Multi-
lateral Trade Negotiations 44 began in 1986, the United States
and Japan submitted proposals to address international intel-
lectual property rights and their enforcement. 145 It was from
the Uruguay Round negotiations that the WTO was derived.146
The WTO was established on January 1, 1995 and replaced
GATT. 147 The WTO not only encompasses the provisions of
GATT, but also addresses a wider range of objectives aimed at
promoting international trade. 148
140 World Trade Organization, Understanding the WTO - The GATT Years:
From Havana to Marrakesh, http://www.wto.org/English/thewto-e/whatis-e/tif e/
fact4_e.htm (last visited Aug. 19, 2008).
141 Id. at 4.
142 See id. at 5-10.
143 Anna-Liisa Jacobson, The New Chinese Dynasty: How The United States
and International Intellectual Property Laws are Failing to Protect Consumers and
Inventors From Counterfeiting, 7 RICH. J. GLOBAL L. & Bus. 45, 51 (2008).
144 The Uruguay Round is the largest trade negotiation to date, taking seven
and a half years and covering almost all trade across virtually every industry.
World Trade Organization, supra note 134.
145 Many developing countries, particularly Brazil and Argentina, opposed in-
tellectual property rights being placed on the negotiating agenda at the Uruguay
Round. See GERVAIS, supra note 139, at 10.
146 World Trade Organization, Understanding the WTO - The Uruguay
Round, http://www.wto.org/english/thewto-e/whatise/tife/fact5_e.htm (last vis-
ited Aug. 19, 2008).
147 Id.
148 See World Trade Organization, Understanding the WTO, http://www.wto.
orglenglisblthewtoe/whatis_e/tife/understanding-e.pdf (last visited Nov. 11,
2007) [hereinafter Understanding the WTO]. As of January 2007, 150 countries
belonged to the WTO, constituting the bulk of the world's trading nations. Id. The
WTO essentially functions as a forum where members can go to negotiate or re-
solve their trade problems. Id. The heart and soul of the WTO are its agreements,
which are negotiated and signed by members and serve as the legal ground rules
for international commerce. Id. Through these agreements, countries are bound
to keep their trade policies within certain established parameters. Id. This as-
sures other member nations that foreign markets will remain open and stable. Id.
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The WTO operates under certain fundamental princi-
ples. 149 For example, under the WTO, members must trade
without discrimination. 150 This is known as most-favored-na-
tion treatment, in which all WTO trading partners must be
treated equally. 151 The WTO also believes in lowering trade
barriers through peaceful and gradual negotiation.152 The WTO
realizes that opening markets requires adjustment and the
agreements allow developing and least developed countries ad-
ditional time to fulfill their obligations. 153 Overall, the WTO's
ultimate goal is to promote principles of fair competition and to
encourage development and economic reform through open
trade. 154
One of the most significant changes from GATT to the WTO
was the incorporation of a more structured dispute resolution
system. 155 WTO agreements are approved by a consensus and
ratified by all members' governments; members are bound by
those agreements and must uphold the rights promised to other
countries.1 56 If a member believes a fellow member has violated
an agreement, the WTO encourages the parties to discuss the
problem and come to a mutual resolution.157 If the members are
not able to resolve the situation on their own, then they have
agreed to use the WTO's system of settling disputes rather than
take action unilaterally.15 8 When the countries have attempted
to, and been unable to settle the dispute on their own, the issue
is brought before the Dispute Settlement Body (DSB). 15 9 The
DSB appoints a panel of experts, who act as a tribunal, to con-
149 World Trade Organization, Understanding the WTO - Principles of the
Trading System, http://www.wto.org/englishlthewtoe/whatise/tife/fact2_e.htm
(last visited Aug. 19, 2008).
150 Id.
151 World Trade Organization, Understanding the WTO - A Unique Contribu-
tion, http://www.wto.org/english/thewto-e/whatise/tife/disple.htm (last visited
Aug. 19, 2008) [hereinafter Dispute Resolution].
152 Id.
153 See infra text accompanying note 128.
154 See id.
155 Dispute Resolution, supra note 151.
156 See Understanding the WTO, supra note 135.
157 Dispute Resolution, supra, note 151.
158 See Understanding the WTO, supra note 135.
159 The DRB consists of all WTO Members. Id.
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sider the case. 160 Once a panel makes a decision, it can only be
rejected by consensus of the DSB.161 If a country loses a dispute
and does not abide by the panel's decision, the WTO has the
power to authorize trade sanctions against the losing party.162
2. The WTO's Framework for Intellectual Property Law
a. The Underlying Principles and Standards of
TRIPS
The Agreement on Trade-Related Aspects on Intellectual
Property Rights (TRIPS) was negotiated at the Uruguay Round
and adopted on April 15, 1994 at Marrakesh. It is an interna-
tional agreement administered by the WTO that establishes a
detailed set of substantive minimum standards that cover
trademarks, copyrights, geographical indications, industrial de-
signs, patents, and undisclosed information.163 The TRIPS
agreement effectively increases harmonization of intellectual
property rights among WTO members. 16 4 According to the
WTO, TRIPS is, to date, "the most comprehensive multilateral
agreement on intellectual property." 6 5 The objectives of the
TRIPS Agreement are to promote international trade and the
adequate protection and enforcement of intellectual property
rights (IPRs). 166 TRIPS recognizes that adequate protection of
IPRs is essential to the promotion of technological innovation
and to the dissemination of technology to the public domain. 167
This is to the mutual advantage of the innovators of technologi-
cal knowledge as well as to those who use it. However, TRIPS
also realizes that promotion of trade and technology should be
160 The panel is chosen with input from the countries in dispute. Id. If the
countries cannot agree on the panel then it is appointed by the WTO Director-
General. Id.
161 Dispute Resolution, supra, note 151.
162 Id.
163 World Trade Organization, Overview: the TRIPS Agreement, http://www.
wto.orgfenglishltratop-e/trips-e/intel2_e.htm (last visited Nov. 11, 2007) [hereinaf-
ter Overview of TRIPS].
164 World Trade Organization, Understanding the WTO - Intellectual Prop-
erty: Enforcement and Protection, http://www.wto.org/englishlthewto-e/whatise/
tif e/agrm7_e.htm (last visited Aug. 19, 2008). The TRIPS Agreement is an at-
tempt to narrow the gaps in the way intellectual property rights are protected
around the world and to bring them under common international rules. Id.
165 Id.
166 TRIPS Agreement , supra note 131.
167 See Overview of TRIPS, supra note 163.
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accomplished in a manner conducive to social and economic wel-
fare.168 From the outset, TRIPS recognized the need to balance
intellectual property rights with social interests. 169 One of the
most adversarial aspects of TRIPS is the dichotomy between
granting pharmaceutical patents and the need for accessible
medicines to protect public health. 70
The TRIPS Agreement was an exercise in compromise be-
tween developed and developing nations. The U.S., the Euro-
pean Union, and other industrialized nations aggressively
pursued strong IPRs while developing countries vehemently re-
sisted even minimum standards of protection.17" Ultimately,
the developed world made concessions in agriculture and textile
trade positions in exchange for developing countries agreeing to
a minimum standard of intellectual property protection. 172
The minimum standards of IPRs adopted under the TRIPS
Agreement must be adhered to by all member countries within
an established transitional period. 173 The Agreement sets the
standards by incorporating the substantive obligations of the
Paris and Berne Conventions. 74 Additionally, TRIPS addresses
168 TRIPS Agreement, supra note 131, art. 7.
169 See id., Preamble.
170 See Barbosa, supra note 68.
171 See Doane, supra note 133, at 473-76.
172 Id. at 476.
173 TRIPS Agreement, supra note 131, arts. 65, 66. Developed countries have
one year to comply with the TRIPS Agreement. Id., art. 65(1). Developing coun-
tries are granted a five year transitional period. Id., art. 65(2). Least developed
countries are given ten years to transition. Id., art. 66(1). On November 29, 2005,
just months before the January 1, 2006 deadline, the LDCs were granted an addi-
tional seven and one-half years to comply with TRIPS. See Press Release, World
Trade Organization, Poorest Countries Given More Time to Apply Intellectual
Property Rules (Nov. 29, 2005), available at http://www.wto.org/English/news-e/
pres05_e/pr424_e.htm. The 2005 reprieve expands on a 2002 extension given to all
LDCs regarding patents on pharmaceuticals. Id. LDCs have until 2016 to provide
full patent protection to pharmaceuticals. Id.
174 PAUL GOLDSTEIN, INTERNATIONAL INTELLECTUAL PROPERTY LAW 96 (Robert
C. Clark, et al., eds., 2001). Goldstein writes:
The Paris Convention for the Protection of Industrial Property (1883) is
important primarily for having obligated its members to offer nondiscrim-
inatory treatment to the nationals of other member countries with respect
to industrial property protection that the member provided for its own
citizens. It also established an international priority system for the regis-
tration of industrial property. The only minimum standards it set were
those governing the protection that members were to provide against un-
fair competition. The Berne Convention for the protection of Literacy and
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a number of inadequacies of these treaties. 175 Countries may
adopt stronger IPRs, so long as those rights do not contradict
any TRIPS provisions. 176
b. The Patent Provisions of TRIPS
This paper only addresses international patent rights
under TRIPS. TRIPS Article 27(1) states that "patents shall be
available for any inventions, whether products or processes, in
all fields of technology, provided that they are new, involve an
inventive step and are capable of industrial application." 177
There are three enumerated exceptions to the general rule of
patentability. 178 The first exception is for inventions contrary to
ordre public or morality. 179 This expressly includes inventions
"dangerous to human, animal, or plant life or health or seri-
ously prejudicial to the environment." 8 0 The second exception
is that members are not required to grant patents for "diagnos-
tic, therapeutic and surgical methods for the treatment of
humans and animals."' 8 ' The last exception is that members
may exclude "plants and animals other than micro-organisms
and essentially biological processes for the production of plants
Artistic Work (1886), in addition to imposing national-treatment obliga-
tions on its members with respect to the literary and artistic works of its
own nationals, establishes certain minimum standards for the protection
of literary and artistic works. However, a number of countries, including
the United States, objected to some of these standards and refused to ad-
here to the Convention.
Id.; see generally J.H. Reichman, Legal Hybrids Between the Patent and Copyright
Paradigms, 94 COLUM. L. REV. 2432, 2434-36 (1994) (discussing the Paris and
Berne Conventions as representing two international approaches to intellectual
property).
175 Two perceived inadequacies of the Paris and Berne Conventions that
TRIPS cures are 1.) the absence of an effective and binding dispute resolution sys-
tem; and 2.) an absence of rules on the enforcement of rights before a national
judicial administrative authority. Moreover, the evolution of the world trading sys-
tem and the rapid increase in technology required a substantial updating of inter-
national intellectual property laws. GERVAIS, supra note 139, at 10. See also
George K. Foster, Opposing Forces in a Revolution in International Patent Protec-
tion: The U.S. and India in the Uruguay Round and Its Aftermath, 3 UCLA J. INT'L
L. & FOREIGN AFF. 283, 287 (1998).
176 TRIPS Agreement, supra note 131, art. 1.
177 Id., art. 27(1).
178 Id.
179 Id.
1so Id., art. 27(2).
181 Id., art. 27(3)(a).
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and animals ... ,182 Under TRIPS, a patent holder has "the
right to prevent third parties from making, using, offering, sell-
ing, or importing their invention."18 3 Like U.S. law, the agree-
ment confers patent rights for 20 years from the date of
filing.18 4 All WTO members must comply with TRIPS but are
allowed the flexibility of incorporating the provisions into their
own legal system and practice.' 8 5
One industry that TRIPS specifically addresses is
pharmaceuticals. At first glance the exception in Article 27(3)(a)
that excludes from patentability diagnostic, therapeutic and
surgical methods, appears to encompass pharmaceuticals. No
doubt this exception was created to promote free use of medical
treatments. Nevertheless, this exception does not apply to
pharmaceuticals. Article 70(8) expressly requires member coun-
tries to grant pharmaceutical patents. 8 6 Many developing
countries had reservations about strengthening IPRs in general
and for pharmaceuticals in particular; however, they realized
that international trade was essential to their economic growth
and the benefits of belonging to the WTO were outweighed by
their concerns over IPRs. l s 7 Recently, these concerns have re-
turned, especially in light of the HIV/AIDS crisis faced by many
developing and least developed countries.' 88
TRIPS provides for some uses of a patent that can be made
without authorization from the patent holder.'8 9 In particular,
Article 31 allows members to issue compulsory licenses.' 90 A
compulsory license permits the use and manufacture of a pat-
ented invention without permission from the patent holder. 191
182 Id., art. 27(3)(b).
183 Id., art. 28(1).
184 Id., art. 33.
185 Id., art. 33.
186 Id., art. 70(8).
187 See Harrelson, supra note 132, at 176.
188 Press Release, World Trade Organization, WTO Members to Press on, Fol-
lowing 'Rich Debate' on Medicines, (June 22, 2001), available at http://www.wto.
org/englislnewse/presO l-e/pr233_e.htm.
189 See TRIPS Agreement, supra note 131, art. 31(b).
190 Id.
191 See Margaret Duckett, Compulsory Licensing and Parallel Importing: What
do they mean? Will they improve access to essential drugs for people living with
HIVIAIDS? (July 1999), www.icaso.org/docs/compulsory-english.htm (discussing
compulsory licenses and parallel importing as methods for increasing access to
AIDS medications).
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Non-authorized use of a patent is permitted if, "prior to such
use, the proposed user has made efforts to obtain authorization
from the right holder on reasonable commercial terms and con-
ditions and that such efforts have not been successful within a
reasonable period of time."192 This requirement can be waived
"in cases of national emergency or other cases of extreme ur-
gency or for public non-commercial use." 193 In these cases the
issuing government must notify the patent holder as soon as
reasonably possible and the patent holder must be paid an ade-
quate remuneration.1 9 4 Each compulsory license is to be consid-
ered on its individual merits and its legal validity is subject to
independent review. 195
Any WTO member may issue a compulsory license to use or
manufacture a patented pharmaceutical, but Article 31(f) of
TRIPS states that the use must be "predominately for the sup-
ply of the domestic market."1 96 This has posed a problem for
numerous developing and least developed countries that have
little or no pharmaceutical manufacturing capabilities. 197 With-
out means to manufacture domestically, any effort to secure
pharmaceuticals from other countries would be in violation of
TRIPS. 198 Developing countries sought exception to this provi-
sion so that they could import pharmaceuticals produced in
countries with manufacturing facilities. 199 This conflict was
one of the issues addressed in the Doha Development
Agenda. 200
192 TRIPS Agreement, supra note 131, art. 31(b).
193 Id.
194 Id., art. 31(b), (h).
195 Id., art. 31(a), (i).
196 Id., art 31(f).
197 Express Pharma Pulse, Article 31(f) & Article 6: Need for Pragmatic Ap-
proach, http://www.expresspharmaonline.com/20021121/patents.shtml (last vis-
ited Aug. 19, 2008).
198 TRIPS Agreement, supra note 131, art 31(f).
199 Thomas A. Haag, TRIPS Since Doha: How Far Will the WTO Go Toward
Modifying the Terms for Compulsory Licensing?, 84 J. PAT & TRADEMARK OFF.
Soc'y 945 (2002).
200 World Trade Organization, Ministerial Declaration of 14 November 2001,
Declaration on the TRIPS Agreement and Public Health, Nov. 20, 2001, available
at http://www.wto.org/english/thewto e/minist_e/min0lemindecl_e.htm [herein-
after Doha Declaration].
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3. The Doha Declaration
In November 2001, the WTO's fourth ministerial confer-
ence convened in Doha, Qatar. 201 WTO ministers felt that many
developing countries were having problems implementing WTO
agreements. 20 2 The TRIPS agreement was one of many issues
on the negotiation agenda. 20 3 One result of these negotiations
was the Doha Declaration on the TRIPS agreement and public
health (Doha Declaration). 20 4 The WTO recognized the serious-
ness of public health problems in developing and least devel-
oped countries and did not want the TRIPS Agreement to
prevent members from taking measures to protect public
health.20 5
The purpose of the Doha Declaration was to clarify the pro-
visions and to resolve the perceived flaws of Article 31 of the
TRIPS Agreement. 20 6 The Doha Declaration affirms that "each
member has the right to grant compulsory licenses and the free-
dom to determine the grounds upon which such licenses are
granted."20 7 Furthermore, the declaration maintains that mem-
bers may themselves determine what constitutes a national
emergency or other circumstance of extreme urgency.208 The
declaration specifies that public health crises related to HIV/
AIDS, tuberculosis, malaria, and other epidemics can qualify as
a national emergency or other circumstances of extreme ur-
gency.20 9 Furthermore, the declaration allows least developed
countries to delay implementation of TRIPS with regard to
pharmaceuticals until 2016.210
201 World Trade Organization, Doha Development Agenda: Negotiations, Im-
plementation and Development, http://www.wto.org/english/tratop-e/dda-e/dda e
.htm (last visited Aug. 19, 2008).
202 Id.
203 World Trade Organization, Understanding the WTO: The Doha Agenda,
http://www.wto.org/english/thewto-e/whatis-e/tife/dohal-e.htm (last visited Oct.
30, 2007).
204 Doha Declaration, supra note 200.
205 Id.
206 See id. 4-5.
207 Doha Declaration, supra note 200, 5(b).
208 See id. 5(c).
209 Doha Declaration, supra note 200, 5(C).
210 See sources cited and accompanying text supra note 128.
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Article 31(f) of TRIPS is addressed in what has become
known as "Paragraph 6" of the Doha Declaration. 211 Paragraph
6 states that the WTO recognizes that countries with little or no
manufacturing capabilities may not be able to effectively issue
compulsory licenses under TRIPS. 212 After much debate, the
Council for TRIPS finally came to a decision that members may
waive their obligations under Article 31(f) of TRIPS if they are a
least developed country or if not, they can show that they have
insufficient or no manufacturing capacities in the pharmaceuti-
cal sector. 213 This allows members without pharmaceutical
manufacturing facilities to import generic medicines from other
countries under a compulsory license. Many commentators
praised this decision and declared it a victory for developing
and least developed nations. 214 Others feel that the decision will
undermine pharmaceutical companies and be a disaster for
open trade.215
B. The Thai Patent Act
Thailand has a relatively brief history with patent law. As
recently as 1964, Thailand's Supreme Court ruled that patent
rights were not enforceable under Thai law.21 6 However, as a
developing nation whose economic development relies on indus-
trialization and technological advancement, the Thai govern-
ment realized the necessity of patent protection. 217 In 1979,
211 World Trade Organization, Implementation of Paragraph 6 of the Doha
Declaration on the TRIPS Agreement and Public Health, http://www. wto.org/en-
glish/tratop-e/trips-e/implem para6_e.htM (last visited Aug. 19, 2008).
212 Doha Declaration, supra note 200, $1 6.
218 WTO General Council, Implementation of Paragraph 6 of the Doha Declara-
tion on the TRIPS Agreement and Public Health, WT/L/540 and Corr. 1 (Sept. 1,
2003), available at www.wto.org/english/tratop-e/trips-e/implem-para6-e.htm
[hereinafter Paragraph 61.
214 C.P. Chandrasekhar & Jayati Ghosh, WTO Drugs Deal: Does it Really Ben-
efit Developing Countries?, HINDU Bus. LINE, INTERNET EDITION, Sept.9, 2003,
available at http://www.thehindubusinessline.com/2003/09/09/stories/2003090900
140900.htm.
215 Id.
216 Jakkrit Kuanpoth, Major Issues in the Thai Patent System, L.J THAILAND
BARRISTERS ASSN., available at THE ONLINE THAILAND LAW JOURNAL (1999), http:ll
www.thailawforum.com/articles/jakpatl.html (last visited Nov. 11, 2007).
217 See Thailand Department of Business Development, History of Department
of Business Development, http://www.thairegistration.commainsite/index.php?id=
4&L=I (last visited Aug. 19, 2008); see also, Kuanpoth, supra note 216.
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Thailand passed its first patent act. 218 This patent system was
enacted as part of Thailand's economic policy to accelerate in-
dustrialization and trade expansion. 219 In 1992, Thailand re-
vised its patent act amending the previous law in such areas as
the "scope of patentable subject-matter, extension of the term of
patent rights, the establishment of a drug price review commit-
tee, and the modification of the process for the grant of compul-
sory licenses."220 In drafting its patent act the Thai Assembly
incorporated many of the basic principles established in the
Paris Convention. 221 The Assembly was also influenced by the
legal paradigm under the Model Law for Developing Countries,
drafted by BIRPI and later WIPO, and the basic rules embodied
in the patent legislations of developed countries. 222 However,
because Thai patent law is in its infancy, there has been little
litigation and few judicial interpretations of the law.223 The
Thai patent act allows compulsory licenses to be issued by the
government on its own behalf or to a private individual.224
Under section 46, a private citizen can apply for a compulsory
license for failure to work the patent.225 Failure to work can
arise in two situations. First, section 46 explicitly states that
the failure to work arises when a patented product has not been
produced or manufactured in Thailand. 226 Importation of a pat-
ented invention is not considered working a patent under this
section.227 The patent holder must utilize the patented inven-
tion in the country personally or through an authorized licen-
218 Kuanpoth, supra note 216.
219 Id.
220 Id. Thailand's revised patent act specifically provides protection for
pharmaceuticals. Id.
221 Kuanpoth, supra note 216.
222 Id.
223 Id.
224 THAi PATENT ACT, § 51 (B.E. 2535). See also THAi PATENT ACT, § 46 (B.E.
2535).
225 THAi PATENT ACT, § 46 (B.E. 2535).
226 Id.
227 See THAI PATENT ACT, § 46 (B.E. 2535). See also Letter from Drs. Jakkrit
Kuanpoth, Associate Professor, Sukhothai Thammathirat University School of
Law, and Jiraporn Limpananont, Associate Professor, Chulalongkorn University,
in Response to PhRMA's Thailand Submission to 2000 USTR NTE Report (Jan. 29,
2000), available at http://www.cptech.org/ip/health/c/thailand/Response-to-Ph
RMAreport.html (last visited Aug. 19, 2008).
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see.228 Secondly, a compulsory license can be granted when the
demand on the Thai market is not fulfilled. This occurs when
the patentee refuses to sell the products protected by the patent
in the Thai market in sufficient quantity, or when such prod-
ucts are sold at an excessive price.229 This section does require
the applicant to have "made an effort to obtain a license from
the patentee having proposed conditions and remuneration rea-
sonably sufficient under the circumstances."2 30
Section 51 of Thailand's Patent Act authorizes the govern-
ment to grant compulsory licenses for the use and production of
patented inventions. 231 Section 51 allows any ministry or de-
partment of the government to exploit the rights of any patent
holder "in order to carry out any service for public consumption"
or "to prevent or relieve shortage of food, drugs or other con-
sumption items or for any other public service."232 This section
does not require prior negotiation with the patent holder in or-
der to issue a compulsory license but it does require that the
patentee must be paid a royalty and must be notified in writing
without delay.2 33
Section 51 further states that the ministry or governmental
department issuing the compulsory license must submit the
amount of remuneration and conditions of the license to the Di-
rector-General. 234 The royalty rate and terms should be set as
agreed upon by the government and the patentee and "the pro-
visions of Section 50 shall apply mutatis mutandis. Section 50
permits the authorizing body to set the rate absent agreement
with the patent holder. 235 In other words, it is inconsequential
whether an agreement is reached with the patent holder - the
government can set the royalty at whatever it likes. The patent
holder's only recourse is to appeal.
228 See Kuanpoth, supra note 216.
229 THAi PATENT ACT, § 46 (B.E. 2535).
230 Id.
231 THAI PATENT ACT, § 51 (B.E. 2535).
232 Sean Flynn, Thai Law on Government Use Licenses, Dec. 18, 2006, http:ll
www.wcl.american.edu/pijip-static/documents/ThailandCLLaw.2.doc?rd=1.
233 THAI PATENT ACT, § 51 (B.E. 2535).
234 Id.
235 THAI PATENT ACT, § 50 (B.E. 2535).
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Section 50 states that the terms of the license, including
the applicable royalty, may be appealed. 236 However, under
Thai law the patent holder has no right to appeal the grounds
for the decision to grant the compulsory license. 237 The govern-
ment may immediately begin to use the license for production
or to purchase generic versions of the patented medicine regard-
less of whether the terms of the license are under appeal.238
IV. CRITICISMS AND CONSEQUENCES
No one would argue that access to drugs and health care is
not a major problem throughout the developing world. And
pharmaceutical companies are an easy target on which to place
the blame. However, instead of shifting the blame onto pharma-
ceutical companies, governments need to take responsibility for
their own citizens. Governments need to address the issues that
contribute to medical inaccessibility such as poverty, poor
health care infrastructure, and lack of trained personnel. With-
out fixing these fundamental problems, the issue of how much
drugs cost is a moot point.
The benefits that modern pharmaceuticals have brought to
the world are incalculable. Pharmaceuticals have eradicated
devastating diseases, developed treatments for hundreds of af-
flictions, and for patients with HIV, these drugs have added
years to their lives and given them some hope for what used to
be an automatic death sentence. Pharmaceuticals have not only
benefited the health of millions of people, but they have also
been economically beneficial as well. Aside from the jobs that
pharmaceutical companies provide and the money that goes
into the American economy, prescription drugs save approxi-
mately three dollars in medical care for every one dollar spent
on medicine. 239
The use of unwarranted compulsory licenses puts the fu-
ture of pharmaceutical companies at risk. The availability of
236 Id.
237 See Flynn, supra note 232, at 4.
238 Id. at 5.
239 PHARMACEUTICAL PROFILE, supra note 104, at 25. For every one dollar spent
on diabetes, $7.10 was saved. Id. For every one dollar spent on cholesterol drugs,
$5.10 was saved, and for every one dollar spent on blood pressure drugs, $4 was
saved. Id.
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new and improved drugs may diminish the quality of as well as
accessibility to affordable drugs. Thailand's use of compulsory
licensing is a misguided attempt to help its citizens. What Thai-
land obviously has not considered is that its imprudent decision
may have put its citizens' future access to medicines in
jeopardy.
A. Criticisms
1. The Ambiguity of TRIPS Concerning Compulsory
Licenses
The nature of international negotiation is compromise. A
consequence of this conciliatory character is that the discus-
sions inevitably result in language that is vague and many
times contradictory. 240 The TRIPS agreement is no exception to
this and it is especially evident in regards to compulsory
licenses.
Article 31 of TRIPS allows countries to waive negotiations
with patent holders before issuing compulsory licenses in cases
of national emergencies, of extreme urgency, and for non-com-
mercial public use. 241 TRIPS does not define any of these enu-
merated circumstances which has led to much confusion and
debate.242 The Doha Declaration attempted to clarify these
broad conditions but only made the situation more uncertain by
allowing countries to determine for themselves what constitutes
a national emergency or a case of extreme urgency.243 By al-
lowing countries such broad latitude in defining a national
emergency, TRIPS is giving its members an overwhelming
amount of discretion in deciding whether or not to issue compul-
sory licenses. While the declaration did identify public health
crises related to HIV/AIDS, tuberculosis, malaria, and other
epidemics as a situations that might qualify as national emer-
gencies, this does not provide much guidance. People in most
240 See generally John A. Ragosta, Unmasking the WTO - Access to the DSB
System: Can the WTO DSB Live up to the Moniker "World Trade Court"?, 31 LAW &
POL'Y INT'L Bus. 739 (2000) (discussing the short comings of the WTO's dispute
settlement system).
241 TRIPS Agreement, supra note 131, art. 31.
242 See, for example, Christopher Arup, TRIPs FORUM: A Matter of Interpre-
tation, http://eprints.vu.edu.au/archive/00000113/01/confctripsforum2004_arup.
pdf (last visited Aug. 19, 2008).
243 Doha Declaration, supra note 200, 5(c).
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countries would consider the HIV/AIDS epidemic a public
health crisis, but does that mean every country should be al-
lowed to seize patent rights?
Although the Doha Declaration gave members the discre-
tion to determine what constitutes a national emergency or a
circumstance of extreme urgency, it was silent on the interpre-
tation of any other language. 244 The only direction the mem-
bers are given is in paragraph 5(a) which asserts that the
provisions of TRIPS should be interpreted by applying the cus-
tomary rules of interpretation of public international law and
read in light of the objectives and principles of the agree-
ment.245 Articles 7 and 8 of TRIPS address its objectives and
principles. 246 Article 7 states that TRIPS objectives are to pro-
tect and enforce IPRs in a manner conducive to social and eco-
nomic welfare. 247 Article 8 allows members to make laws to
protect public health and to prevent abuses of IPRs by right
holders or practices that restrain trade.248 On issues of inter-
pretation, one side is going to want to interpret the language in
favor of public health and the other side in favor of IPRs. Both
issues are part of the objectives and principles of TRIPS, so who
is right? Although TRIPS specifically recognizes the importance
of affordable medicine, the purpose and intent behind the for-
mation of the WTO was to promote free trade and to address the
growing issues in international intellectual property law. 249
Some would argue that the WTO's purpose is not humanitarian
in nature and that its agreements should be read in view of its
original purposes and not as advocating health care.
There are several terms in the compulsory license provi-
sions of TRIPS that are open to various interpretations. One
term whose meaning was left open is "public non-commercial
use." The use of the term "non-commercial" leaves the door open
244 Sharifah Rahma Sekalala, Beyond Doha: Seeking Access to Essential
Medicines for HIV/AIDS Through the World Trade Organisation, http://site
resources.worldbank.org/INTRAD/Resources/SSekalala.pdf (last visited Aug. 19,
2008).
245 Doha Declaration, supra note 200, 5(a).
246 TRIPS Agreement, supra note 131, arts. 7-8.
247 TRIPS Agreement, supra note 131, art. 7.
248 TRIPS Agreement, supra note 131, art. 8.
249 World Trade Organization, Understanding the WTO - What is the World
Trade Organization?, http://www.wto.org/english/thewtoe/whatise/tife/factle.
htm (last visited Aug. 19, 2008).
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to various interpretations: West's Legal and Commercial dic-
tionary defines "commercial" as a generic term applied to buy-
ing and selling. 250 By its very definition the term is nonspecific.
Whoever manufactures the drug is not going to give it away, so
that would fall within the definition of commercial. Does "public
non-commercial use" mean only governments can produce the
licensed generic drugs, as opposed to private manufacturers?
Regardless of whether it is a government or private manufac-
turer, the producer of the drugs will make money on the drug. Is
that considered commercial? Without any guidance countries
will use their own discretion to determine what constitutes
"non-commercial."
TRIPS also neglects to define what adequate remuneration
is and how it should be calculated. 251 Developed countries
would like full compensation, while developing and least devel-
oped countries would like little or none. 25 2 Should it depend on
market value? On profit margin? On the GDP of the issuing
country? There are many elements that can be looked at to de-
termine compensation and TRIPS provides no guidance other
than that it shall be "adequate" and "take in to account the eco-
nomic value to the importing Member of the use that has been
authorized in the exporting Member. '253 Without any defined
boundaries or direction, who is to say what is adequate and
what is not? Thailand feels that 0.5% is adequate; many com-
mentators disagree and claim it is far below industry norms of
4-10%.254 There is no consensus among countries as to how a
250 WEST'S LEGAL AND COMMERCIAL DICTIONARY (1st ed. 1986).
251 Do Hyung Kim, Research Guide on TRIPS and Compulsory Licensing: Ac-
cess to Innovative Pharmaceuticals for Least Developed Countries, GLOBALEX,
Feb. 2007, http://www.nyulawglobal.org/globalex/TRIPSCompulsory-
Licensing.htm (last visited Aug. 19, 2008) ("Furthermore, TRIPS requires coun-
tries utilizing compulsory licensing to pay "adequate remuneration" without speci-
fying a method of calculation.").
252 See Bryan C. Mercurio, TRIPS, Patents, and Access to Life-saving Drugs in
the Developing World, 8 MARQ. INTELL. PROP. L. REV. 211, 242-45 (2004).
253 TRIPS Agreement, supra note 131, art. 31(h).
254 Daniel M. Putterman, Model Material Transfer Agreements for Equitable
Biodiversity Prospecting, 7 COLO. J. INT'L ENVTL. L. & POL'Y 149 (1996); James
Love, Remuneration Guidelines for Non-Voluntary Use of a Patent on Medical
Technologies (2005), http://www.who.int/medicines/areas/technical cooperation/
WHOTCM2005.1 OMS.pdf (discussing state practice regarding the determination
of reasonable royalties and adequate renumeration as nations establish the condi-
tions under which they may issue compulsory licenses).
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reasonable royalty should be calculated. In the United States,
courts have developed a set of guidelines known as the Georgia
Pacific factors. 25 5 But even within the United States there is
argument over whether these factors are economically appropri-
ate.256 This lack of clarity will only lead to confusion and the
potential for abuse.
The Council for TRIPS decided that members could import
pharmaceuticals under a compulsory license if they are a LDC
or if they can show they have insufficient or no pharmaceutical
manufacturing facilities. 257 The Council failed to provide any
255 In the United States, the Georgia Pacific guidelines have provided the
framework for determining royalties for patent infringement for over 30 years. In
Georgia Pacific, the court established 15 factors to be used to determine the mone-
tary payments that would compensate for patent infringement. 1) The royalties
received by the patent holder for licensing the patent, proving or tending to prove
an established royalty, 2) the rates paid by the licensee for the use of other similar
patents, 3) the nature and scope of the license, such as whether it is exclusive or
nonexclusive, restricted or non-restricted in terms of territory or customers, 4) the
patent holder's policy of maintaining its patent monopoly by licensing the use of
the invention only under special conditions designed to preserve the monopoly, 5)
the commercial relationship between the patent holder and licensee, such as
whether they are competitors in the same territory in the same line of business or
whether they are inventor and promoter, 6) the effect of selling the patented spe-
cialty in promoting sales of other products; the existing value of the invention to
the patent holder as a generator of sales of non-patented items; and the extent of
such derivative or "convoyed" sales, 7) the duration of the patent and the term of
the license, 8) the amount that the patent holder and a licensee would have agreed
upon at the time the infringement began if they had reasonably and voluntarily
tried to reach an agreement, 9) the opinion testimony of qualified experts, 10) the
portion of the realizable profit that should be credited to the invention as distin-
guished from any non-patented elements, manufacturing process, business risks or
significant features or improvements added by the infringer, 11) the portion of the
profit or selling price that is customary in the particular business or in comparable
businesses, 12) the extent to which the infringer used the invention and any evi-
dence probative of the value of that use, 13) the nature of the patented invention,
its character in the commercial embodiment owned and produced by the licensor,
and the benefits to those who used it, 14) the utility and advantages of the patent
property over any old modes or devices that had been used; and 15) the established
profitability of the patented product, its commercial success and its current popu-
larity. Georgia-Pacific Corp. v. United States Plywood Corp., 318 F. Supp. 1116,
1120 (1970).
256 See generally William Choi & Roy Weinstein, An Analytical Solution to
Reasonable Royalty Rate Calculations, 41 L.J. & TECH 49 (2001) (explaining the
Nash Bargaining System as a supplement to the Georgia Pacific factors); see also
Roy J. Epstein & Alan J. Marcus, Economic Analysis of the Reasonable Royalty
Rate: Simplification and Extension of the Georgia Pacific Factors, available at
http://www.royepstein.coml/epstein-marcus-jptos.pdf.
257 Paragraph 6, supra note 225.
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guidelines as to "insufficient manufacturing capacities." 258 The
plain meaning of the text would likely indicate that the issuing
country does not have manufacturing capabilities to produce
sufficient quantities of the drug. Thailand is not a LDC and be-
cause it has been producing GPO-Vir for years it is safe to say it
has sufficient manufacturing capacity, yet it has begun import-
ing efavirenz from India.259 Under the plain meaning of the text
Thailand would clearly be in violation of TRIPS. On the other
hand, perhaps "insufficient" refers to the quality of product. In
that case Thailand would not be in violation of TRIPS since
their manufacturing plants are not up to WHO standards. 260 To
avoid the abuse of TRIPS and compulsory licenses the WTO
needs to establish what its language means, otherwise it is open
to interpretation.
These are issues the WTO needs to address. The WTO
needs to provide more concrete guidelines and definitions as to
what justifies the issuance of a compulsory license; it should not
be left to the discretion of the issuing country. Furthermore, a
country seeking a license should first be required to make an
effort to acquire the drug from the patent holder. It is only fair
that under any circumstances, emergency or not, the patent
holder be afforded the opportunity to provide the drug at an eq-
uitable price. If negotiations with the patent holder are unsuc-
cessful and it has been reasonably determined that a license
should be issued, then remuneration should be determined by
an independent WTO committee, the patent holder, and the is-
suing country. Factors such as the importing country's GDP,
rates paid for licenses of similar patents, cost of production, the
nature and scope of the license, and therapeutic value of the
medicine should be considered, as well as any other issues the
committee deems relevant.
Although compulsory licenses are subject to review under
TRIPS, this can be a lengthy process and the DSB does not
grant preliminary injunctions. 261 Additionally, it has been ar-
258 Id.
259 Hookway & Zamiska, supra note 8.
260 Apinya Wipatayotin, Certification Urged for AIDS Drug, New GPO Produc-
tion Plant is Needed First, BANGKOK POST, Jan. 5, 2006, available at http://www.
aegis.org/news/bp/2006/BP060101.html (last visited Aug. 19, 2008).
261 Aditi Bagchi, Compulsory Licensing and the Duty of Good Faith in TRIPS,
55 STAN. L. REV. 1529, 1535-40 (2003).
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gued that the DSU of the WTO has many flaws and litigation
over how negotiated agreements should be interpreted has led
to the creation and imposition of obligations that members
never agreed to.262 In light of the uncertainty that surrounds
TRIPS' provisions for compulsory licenses, it is critical that the
WTO address these issues and provide some clarity and
uniformity.
2. Demonization of Pharmaceutical Companies
The focus on patents and prices of pharmaceuticals ignores
the complexity of access to health care issues and ultimately
prevents policy makers from coming up with any real solutions
to the problem. Even the WHO and patient groups have recog-
nized that this single-minded focus on drug prices is simplistic.
The European Coalition of Positive People publicly stated with
regard to HIV/AIDS drugs that "focusing on patent protection is
'simplistic and fails to take into account the serious practical
problems that need to be addressed."' 263 Drugs could be free
and still not be appropriately used without adequate health
care systems and infrastructures in place. Moreover, they
would rapidly become ineffective due to drug resistance. Kassim
Sidibe, a minister of the National Fight Against AIDS, summed
up the issue well when he said, "cheap drugs are good, free
drugs are better, but they are only a piece of the puzzle."264 It is
clear the issues of patents and prices of drugs should not be the
262 See generally John Ragosta et al., WTO Dispute Settlement: The System is
Flawed and Must Be Fixed, 37 INT'L LAWYER 697 (2003) (arguing that binding arbi-
tration is an inappropriate method of dispute settlement when many terms and
provisions of the agreements are ambiguous).
263 2000 Foreign Policy Overview and the President's Fiscal Year 2001 Foreign
Affairs Budget Request: Hearings Before the Subcomm. on African Affairs and Sub-
comm. on Western Hemisphere, Peace Corps, Narcotics and Terrorism and the
Comm. on Foreign Relations, 106th Cong. 238 (2000) (statement of Dr. Harvey E.
Bale Jr., Director-General, International Federation of Pharmaceutical Manufac-
turers Association, Geneva, Switzerland), available at http://frwebgate.access.gpo.
gov/cgi-bin/getdoc.cgi?dbname=106_senate hearings&docid=f:63628.pdf [hereinaf-
ter Bale Testimony] (testifying before the Senate on AIDS in Africa).
264 Douglas Farah, Seeking a Remedy for AIDS in Africa, WASH. POST, June 12,
2001, at A17 (quoting Kassim Sidibe).
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primary concerns when some countries cannot even afford to
use drugs that have been donated to them.265
Access to even the most basic and off-patent medicines is
often poor in developing and least developed countries. Patent
protections cover less than 5% of the medicines on the WHO's
essential drugs list.266 Many least developed countries still do
not have even a rudimentary patent system in place267 and
those that are WTO members are not required to implement
patent systems until 2016.268 A study in the Journal of the
American Medical Association looked at the status of fifteen
AVRs in 53 African countries and found that two of the drugs
were not patented in any of the countries, four were only pat-
ented in South Africa, and eleven of the drugs were not pat-
ented in more than half the countries. 269 Despite the largely
non-existent patent protection, these countries still lack access
to these drugs.270 Furthermore, in countries where patent pro-
tection has been introduced in the past decade, there has been
no significant impact on access to medicines.271
Pharmaceutical companies have been singled out as the
bad guys. NGO's and even some governments portray pharma-
ceutical companies as greedy, heartless, and evil corporate mon-
sters that fuel the injustices of the world.272 These groups see
patents as the mechanism for this injustice.27 3 Opponents, and
even some advocates, of pharmaceutical companies describe
265 Nevirapine is donated to African countries by Boehringer Ingelheim but is
rarely used. Id. Nevirapine is used in preventing mother to child HIV transmis-
sion during birth. Id. Attaran & Gillespie-White, supra note 118, at 1891.
266 Harvey E. Bale Jr., Patents and Public Health: A Good or Bad Mix?, http://
www.cnehealth.org/pubs/bale-patents-and-publichealth.htm (last visited Apr.
20, 2008).
267 See Attaran & Gillespie-White, supra note 118.
268 See Kevin Kennedy, The 2005 TRIPS Extension for the Least Developed
Countries: A Failure of the Single Undertaking Approach?, 40 INT'L LAWYER 683,
684 (2006).
269 Attaran & Gillespie-White, supra note 118.
270 Id.
271 Bale, supra note 266.
272 See Richard A. Epstein, Editorial, The Myth of the Big Bad Drug Compa-
nies; They're not Greedy, They're over-regulated. The Result is Fewer Pills to Cure
our Ills, L.A. TIMES, Dec. 22, 2006, at A39.
273 See Mike Adams, Bad Patents, Evil Corporations and the Rise of Intellec-
tual Imperialism, NATURAL NEWS, Mar. 1, 2008, http://www.natural news.con/
z022755.html.
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patents as instruments that create "monopolies." 274 This is a
completely inaccurate statement. First, patents give exclusivity
rights to a single drug or vaccine, not multiple or entire classes
of drugs and vaccines. This does not constitute a monopoly since
there are usually alternative treatments to any medicine. For
instance, there are a minimum of six patented protease inhibi-
tor AVRs for the treatment of AIDS.275 The existence of multiple
treatment options, spurred by patent protection, ensures medi-
cal choice and price competition. Second, although a patent
term is technically for 20 years, the patent holder actually only
has 5 to 10 years to recover investment costs and to fund new
research, since patents are applied for early in the development
process and it typically takes 12-15 years of tests and FDA re-
view for new drugs to reach patients.2 7 6
Opponents also like to argue that it does not matter if pat-
ents increase innovation because it is pointless to develop medi-
cations that the poor cannot afford.277 They contend that the
discovery of new treatments is not a sufficient reason to advo-
cate patent protection when those new treatments will also en-
joy strong patent protection and will thus be out of reach to the
world's indigent nations.27 8 This argument is illogical and in-
herently flawed. First, is it better that no one should get the
benefit of new and improved medicines because they are not
available to everyone? By this logic it is all or nothing, which is
even more inherently unjust than the imperfect access that poor
countries have now. Secondly, patent protection is temporary.
After a patent expires, not only are generic brands available to
all, but the knowledge behind the patent has been available in
the public domain so that others can use it to develop new and
better drugs. If innovation becomes stagnant and new medica-
tions are not developed, no one, including the poor, will have
access.
274 Martin Foreman, Don't let TRIPS Trip up Access to Essential Drugs, PAN
AMERICAN HEALTH ORGANIZATION, http://www.paho.org/englishldd/pin/Numberl6-
last.htm (last visited Aug. 19, 2008).
275 Bale, supra note 266.
276 Id.
277 See Julian MorrisMercantilism Today: How a Dead Philosophy Comes
Back to Life, NATIONAL REVIEW, Sept. 15, 2003, available at http://www.policynet
work.net/main/article.php?article-id=584 (last visited Aug. 19, 2008).
278 See generally Jamie Crook, Balancing Intellectual Property Protection with
the Human Right to Health, 23 BERKELEY J. INT'L L. 524 (2005).
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B. The Consequences of Inaction
Allowing countries to issue compulsory licenses at whim
sets a dangerous precedent. Without firm meaning affixed to
TRIPS provisions, countries will interpret the agreement how-
ever they want and in whatever way benefits them regardless of
the long-term consequences. There is a critical need for more
narrow definitions of TRIPS in order to ensure uniform
interpretation.
1. Domestic Consequences: US Consumers and
Pharmaceutical Companies.
High-technology industries and the pharmaceutical indus-
try in particular are an integral part of the American econ-
omy.27 9 The Pharmaceutical industry has developed and
produced dozens of life-saving and life-enhancing medications.
They have developed treatments for cancer, heart disease, dia-
betes, and HIV/AIDS, and have changed the lives of millions of
people. The TRIPS agreement as it stands threatens the ability
of pharmaceutical companies to realize profits and support
their R&D. It is important to protect the industry to ensure
profitability and in effect ensure the continued development of
vital new medicines.
a. Compulsory Licenses Will Diminish
Pharmaceutical Innovation
Weak IPRs threaten the discovery and development of new
medications. Private industry funds virtually all discovery and
development of any new drug.28 0 Investor support for pharma-
ceutical companies depends on the expected returns of a rela-
tive handful of products.28 1 Strong patent protection helps
assure investors that their high-risk investments might pay off
down the line.28 2 Conversely, without confidence that discovery
279 Claude E. Barfield & Mark A. Groombridge, Parallel Trade in the Pharma-
ceutical Industry: Implications for Innovation, Consumer Welfare, and Health Pol-
icy, 10 FORDHAM INTELL. PROP. MEDIA & ENT. L.J. 185, 208 (1999) (stating that the
pharmaceutical industry is "projected to invest over $20 billion in the United
States... ").
280 United States State Department, Focus on Intellectual Property Rights,
http://usinfo.state.gov/products/pubs/intelprp/cost.htm (last visited Aug. 19, 2008).
281 See id.
282 See Masia, supra note 100.
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of a new drug or vaccine can produce a profit, investors in phar-
maceutical firms will invest their money elsewhere. 28 3 Pharma-
ceutical companies rely on patents to protect their research and
their profitability. Patents ensure exclusivity in the market
which allows companies to recoup their R&D investment, in-
vestment in failed compounds, and to make a profit. Without
these assurances there is little incentive for inventors to share
their invention with the public. Without exclusivity the best
way for an inventor to make a profit is to keep the invention a
secret, depriving others of the opportunity to build upon those
findings. 28 4 Without dependable patent protection pharmaceu-
tical companies will not only have trouble bringing in new in-
vestors but they may also have problems with their current
investors to whom the companies owe certain duties.28 5 Like
any other public corporation, pharmaceutical companies must
answer to their stock holders and if they can not produce the
results their investors expect they may face a whole host of le-
gal problems.
The fact is, there is no cure or vaccine for HIV/AIDS. 28 6
There are viral strains resistant to current drugs and resistance
will continue to develop. 2 7 There is a very real need for new
drugs beyond first and second line therapies. 288 There is also a
need for new drugs with easier administration, including
medicines that only need to be taken once or twice a day, fixed
dose combinations, and improved pediatric formulations. 28 9
Right now there are more than 20 ARVs available but there are
30 more still in human trials. 290 There is a need for a vaccine
283 Id.
284 See Lisa C. Pavento, et al., International Patent Protection for HPV-Related
Therapies: Patent Attorneys' Perspective, 17 EMORY INT'L L. REV. 919, 919 (2003).
285 The predominant view on corporate responsibility in the U.S. is that "corpo-
rations have no specific social responsibilities beyond profit-maximizing for the
benefit of shareholders but that such profit maximizing must occur within the con-
fines of the law, without deception or collusion." Williams, supra note 12, at 713-
14.
286 ThinkHIV, Is There a Cure or Vaccine for HIV/AIDS?, http://www.thinkhiv.
org/dp/node/654 (last visited Aug. 19, 2008).
287 amfAR, Basic Facts About HIV/AIDS, http://www.amfar.orgcgibin/iowa/
abouthiv/record.html?record=7 (last visited Aug. 19, 2008).
288 Bale, supra note 266.
289 G8 Summit, supra note 13, at 13.
290 Avert, Table of Approved AIDS Drugs, http://www.avert.orgldrugs-table
.htm (last visited Aug 19, 2008).
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and of the 75 new drugs in trials, 15 are vaccines. 291 If oppo-
nents of pharmaceutical companies want to fight AIDS, finding
a cure or vaccine is the best way to do it. In order for that to
happen it is imperative that new innovation not be hindered.
b. U.S. Consumers Will Bear the Burden of
Pharmaceutical R&D Costs
Another consequence of weak IPRs will be the unfair bur-
den of R&D costs that that U.S. consumers will have to bear.
American consumers already assume a large part of pharma-
ceutical and biotech R&D costs. 292 Although the pharmaceutical
market for developing countries is increasing, it is still the U.S.,
Europe, and Japan that account for the majority of sales. 293 If
pharmaceutical companies lose all their revenues from develop-
ing countries, U.S. prices are going to increase to make up for
those losses. There are already millions of Americans that are
without insurance and cannot afford health care.294 An increase
in prices will only exacerbate the problem.
This is a consequence that will primarily affect the United
States. Many other developed countries have socialized
medicine that allows them to obtain drugs at below market
price.295 In this type of system, the government has almost total
control over the health care market and uses this control to ne-
gotiate lower prices for bulk drugs.296 Even though these coun-
tries get discounted prices there are also many drawbacks to
the system.297 In the U. S. we have a free market system and
291 Id.
292 See PhRMA Meets with Thai Health Minister, supra note 16.
293 See Hookway & Zamiska, supra note 8.
294 CENTER FOR DISEASE CONTROL, HEALTH INSURANCE COVERAGE: EARLY RE-
LEASE OF ESTIMATES FROM THE NATIONAL HEALTH INTERVIEW SURVEY, 2006 (2007),
http://www.cdc.gov/nchs/data/nhis/earlyrelease/insur200706.pdf (last visited Aug.
19, 2008).
295 Doug Pibel, Sarah van Gelder, Health Care: It's What Ails Us, YES! MAGA-
ziNE, Fall, 2006, http://www.yesmagazine.org/article.asp?ID=1498 (last visited
Aug. 19, 2008).
296 See Cost of Prescription Drugs, supra note 11.
297 Many times governments will not pay for the newest medicines available so
patients in these countries will not have access to what may be the best drugs
available. Additionally, the patients in these countries do not have as many
medicines to choose from when designing individual treatment plans. Another
drawback of this system is that generic medicines will often cost more in those
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the prices are determined by market forces and competition. 298
When patents are broken by compulsory licenses and pharma-
ceutical profits are threatened, it is the free market systems
that will see the biggest increase in prices. If drug prices in-
crease substantially it is likely insurance premiums will also in-
crease, leaving many Americans unable to afford insurance.
The rationalization behind compulsory licenses is to assist peo-
ple in developing countries but the fact is, it is likely to harm
American consumers who will no longer be able to afford
medication.
2. Foreign Consequences: Thailand and Other
Developing Countries.
According to the World Bank, Thailand's overall growth
performance is not keeping pace with its neighboring countries.
Thailand's GDP grew by 5% in 2006, slightly higher than in
2005.299 However, Southeast Asia has grown 5.5%.300 China is
averaging 10% and Vietnam 8%.301 Clearly competition for for-
eign investment, direct or indirect, remains strong. Foreign di-
rect investment has "transferred amazingly little tacit
knowledge and technology, as only a handful of companies have
set up research establishments in Thailand. '30 2 It is no wonder
with Thailand's conspicuous lack of respect for intellectual
property protection. Based on World Bank recommendations, to
further develop its economy, Thailand needs to move towards a
knowledge economy that promotes innovation. 30 3
countries than in countries with free markets systems. See COST OF PRESCRIPTION
DRUGS, supra note 11.
298 Id.
299 THAILAND BOARD OF INVESTMENT, THAILAND INVESTMENT REviEw (2007)
http://www.boi.go.th:8080/issue/200706_17_6/cover.htm (last visited Aug. 19,
2008).
300 Asian Development Bank, Asian Development Outlook 2006 Update - De-
veloping Asian and the World - Subregional Summaries, http://www.adb.org
documents/books/ado/2006/update/partOlO4O4.asp (last visited Aug. 19, 2008)
(stating that the entire subregion had an average growth of 5.4%.).
301 VietNamNet Bridge, ADB: 7.8% Economic Growth for Vietnam in 2006,
VIETNAMNET, July 4, 2006, http://english.vietnamnet.vn/biz/2006/04/558167/ (last
visited Aug. 19, 2008); ChinaDaily, China's GDP grows 10.7% in 2006,
CHINADAILY, Jan. 25, 2007, http://www.chinadaily.com.cn/china/200701/25/content
792311.htm (last visited Aug. 19, 2008).
302 World Bank, supra note 20.
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Compulsory licenses have been viewed as the solution to
the drug access issue. Proponents of compulsory licensing only
view the issue in terms of decreased consumer prices. However,
what they fail to see is that these benefits are small and the
long term damage of widespread use of compulsory licensing
will be substantial. The WTO is encouraging companies in de-
veloping countries, such as India and Korea, to shift from man-
ufacturing generic drugs towards pursuing their own
innovative research in pharmaceuticals and biotechnology. 30 4
However, if lax compulsory licensing rules are promulgated,
both the patients and the economies of these countries will ulti-
mately suffer when new competitors withdraw, and companies
revert to the business strategy of replicating medicines others
have researched, discovered, and developed.
Without respect for intellectual property, many developing
and least developed countries' industries and patients risk los-
ing out on the benefits of modern genome-based research that is
increasingly the basis of pharmaceutical and biomedical innova-
tion.30 5 Thus, the real global threat is that without strong and
effective international intellectual property rights the disparity
between developed and developing countries will become
greater in the future.
CONCLUSION
The pharmaceutical industry has provided the world with
hundreds of life-saving drugs and vaccines. These efforts come
largely from the ability to protect their research and develop-
ment through patents. It is crucial that pharmaceutical compa-
nies be able to realize a profit or there will no longer be any
incentive to invest in the development of new medicines and/or
we risk drug prices in the U.S. climbing even higher. Impover-
ished people worldwide deserve access to medication but com-
pulsory licenses are not the solution. Compulsory licensing has
serious and far reaching consequences; it is a short term rem-
edy to a long term problem. If the WTO continues to allow the
broad interpretation of TRIPS in which compulsory licenses can
304 Bale, supra note 266.
305 Id.
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be abused, everyone will lose out on the life-saving and enhanc-
ing benefits that pharmaceutical and biotech companies
provide.
53
